4.1 Bupropion intake creates 3-Chlorocathinone (Hydroxybupropion), 3-Chloroephedrine (Erythrohydrobupropion), 3-Chloropseudoephedrine (Threohydrobupropion) and 3-Chloro-hydroxyphenmetrazine (S,S- and R,R-Hydroxybupropion) analogues via metabolism.

5. Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice

5.1 Bupropion’s metabolites are primarily responsible for its convulsive effects in animals, with a rank order potency of Hydroxybupropion > Threohydrobupropion > Erythrohydrobupropion > Bupropion.

6. Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice

6.1 S,S-Hydroxybupropion is active against Nicotine reward, and partially substitutes for Nicotine.

7. CYP2B6 and bupropion’s smoking cessation pharmacology: the role of hydroxybupropion

7.1 Having Hydroxybupropion serum levels of 700ng/mL (2.8μM) makes Bupropion effective for smoking cessation. Below this threshold, Bupropion does not aid smoking cessation. Hydroxybupropion is largely responsible for Bupropion’s antismoking effects. Hydroxybupropion levels predicted successful smoking cessation and continued abstinence, while Bupropion levels did not.

8. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state

8.1 Poor CYP2B6 metabolizers have lower antismoking efficacy.

8.2 Bupropion is metabolized by CYP2B6, and a genetic variant of this enzyme has large effects on efficacy in MDD and smoking cessation.

9. Synthesis and Characterization of In Vitro and In Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation

10. Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding

11. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach

12. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects

13. Bupropion and Bupropion Analogs as Treatments for CNS Disorders

14. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults

14.1 Low quality evidence suggests use in attention-deficit/hyperactivity disorder (ADHD).

15. Practice patterns of bupropion co-prescription with antipsychotic medications

15.1 Bupropion appears to be underutilized for smoking cessation in schizophrenia, presumably due to the thought that its dopaminergic (DAergic) effects may exacerbate psychosis. This, however, is uncommon, likely because Bupropion is not substantially DAergic, but rather is predominantly noradrenergic (NEergic) in its action.

16. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials

17. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant

17.1 Bupropion has high-quality evidence of superiority to placebo against depression, and comparable efficacy to other antidepressants when compared head-to-head. Most studies show increased efficacy compared to monotherapy when used with another agent when used as an add-on.

17.2 Bupropion has a very low rate of sexual side effects compared to serotonergics, and may improve the sexual dysfunction caused by SSRIs. Bupropion is more likely to cause weight loss than gain.

18. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

18.1 Bupropion is not clinically serotonergic in any meaningful regard.

18.2 Bupropion is an NE-DA reuptake inhibitor (NDRI). It is also a noncompetitive antagonist at nicotinic acetylcholine (ACh) receptors (nAChRs), mostly via its metabolites.

18.3 The brain:plasma ratio is ~10:1.

18.4 Therapeutic doses lead to brain levels of Bupropion and its metabolites that are above the IC50s for the DA transporter (DAT) and NE transporter (NET) throughout the typical 12h dosing interval for Bupropion SR.

18.5 Bupropion treatment prevents the development of SAD relapse.

18.6 Most frequent side effects were dry mouth 16%, nausea 12.5%, and insomnia 10.5%.

18.7 Seizure risk is 0.1% in the general population, and 0.4% for patients on Bupropion IR 450mg/d. At Bupropion IR 600mg/d, the risk jumps to 4%.

19. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release

19.1 Due to the bulky amine substituent, Bupropion is not an NE-DA releasing agent (NDRA), but rather an NDRI. Bulky N-substituted cathinones are not substrates of NET or DAT, nor are they releasing agents.

19.2 Bupropion itself has a DAT IC50 of 304-945nM.

20. Rates of Anomalous Bupropion Prescriptions in Ontario, Canada

21. Bupropion increases striatal vesicular monoamine transport

21.1 Bupropion rapidly, reversibly, and dose-dependently increased striatal DA uptake by VMAT2, an effect common to DRIs. This depends on D2 receptor agonism, as it was reversed with a D2 antagonist.

22. Possible involvement of sigma‐1 receptors in the anti‐immobility action of bupropion, a dopamine reuptake inhibitor

22.1 Bupropion is a σ1 agonist. Its antidepressant-like effects in an animal model depend on σ1. The addition of σ1 agonists turned a sub-effective dose of Bupropion into an effective one, and σ1 antagonists blocked the antidepressant-like effects in the forced swim test (FST) in mice.

23. Revisiting bupropion anti-inflammatory action: involvement of the TLR2/TLR4 and JAK2/STAT3

23.1 Bupropion may be pro-inflammatory at supraphysiologic levels of 50-100μM in vitro.

24. Bupropion for Interferon-Alpha-Induced Depression in Patients with Hepatitis C Viral Infection: An Open-Label Study

24.1 Bupropion reduces depressive and negative somatic effects induced by interferon-α (IFN-α) treatment for Hepatitis C (HepC). 90% of the 10 (9/10) participants responded to IFN-α, as compared to 60% in most situations. However, the sample size was low, and so it is difficult to draw any conclusions.

25. 15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL

25.1 Bupropion is available in IR, SR, and XL, for 3x/d, 2x/d, and 1x/d administration. These are bioequivalent, dosage-wise. Bupropion XL provides the lowest bedtime plasma levels, which may improve the sleep disruption potential.

25.2 Bupropion separated significantly from placebo in preventing MDD relapse. Bupropion halved the risk of depressive relapse. Time to relapse was 44w in the Bupropion group and 24w in the placebo group.

25.3 Bupropion had a lower chance of conversion to mania in bipolar I disorder (BDI) than Desipramine over 1y, despite having comparable efficacy for BD depression.

25.4 Bupropion is more effective than placebo for weight loss. Bupropion causes some weight loss in higher-BMI users, while no weight change is observed in low-to-middle weight people.

25.5 Bupropion SR 300mg/d is not associated with increased risk of seizures.

25.6 Bupropion + Nicotine patch was more likely to result in hypertension than either group alone.

26. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment

26.1 Firing rates of NE neurons are reduced by 80% with 30mg/kg (an equivalent dose to 338mg/d for a 70kg human) by long-term and acute administration, similarly to other amphetamine derivatives. This is caused by α2 agonism by NE, providing negative feedback on its own release.

26.2 At the highest concentration, Bupropion increased the firing rate of serotonin (5-HT) neurons by 2x, an effect that depended on NE.

27. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder

27.1 After 12w of treatment, Bupropion increased serum brain-derived neurotrophic factor (BDNF) by 22.7% in MDD patients, and decreased tumor necrosis factor-α (TNF-α).

28. Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics

29. Analgesic and anti-inflammatory activities of bupropion in animal models

29.1 40mg/kg IP in mice reduced acetic acid-induced abdominal writhing, prevented both initial (nociceptive) and later (inflammatory) stages of formalin-induced behavior, and showed significant analgesia in the hot plate test. This indicated that Bupropion displays analgesic effects in mice.

29.2 Bupropion 40mg/kg IP showed considerable anti-inflammatory activity against carrageenan

29.3 Lowers production of TNF-α and IFN-γ

29.4 Bupropion may be effective for neuropathic pain.

29.5 Bupropion is not superior to placebo for non-neuropathic lower back pain.

30. Bupropion Administration Increases Resting-State Functional Connectivity in Dorso-Medial Prefrontal Cortex

30.1 Compared to placebo, 7d of Bupropion increased resting-state functional connectivity (RSFC) between the dorsomedial prefrontal cortex (dmPFC) and the posterior cingulate cortex (PCC) and the precuneus cortex in healthy humans. These are key nodes in the default-mode network (DMN).

31. Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent

31.1 Bupropion facilitates the acquisition of Nicotine-induced conditioned place preference (CPP) in rats, a measure of reward.

31.2 Bupropion inhibits Nicotine withdrawal in animal models and humans.

31.3 Bupropion attenuates Nicotine-induced Nicotine reinstatement in rats, but there are large interindividual differences.

32. Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys

32.1 High doses of Bupropion and S,S- and R,R-Hydroxybupropion fully substitute for Methamphetamine in male rhesus monkeys. Nicotine substitutes as well, so nAChR antagonism may be involved in these effects.

33. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence

33.1 Bupropion reduced Methamphetamine-induced DA efflux in vitro.

34. Bupropion SR worsens mood during marijuana withdrawal in humans

34.1 Bupropion produced no negative interactions with Cannabis in active users, but worsened irritability, negative mood, restlessness, and trouble sleeping during Cannabis withdrawal.

35. Bupropion in Depression: I. Biochemical Effects and Clinical Response

35.1 Plasma Homovanillic acid (HVA; a DA metabolite) increased significantly in nonresponders but not responders.

35.2 Bupropion reduced whole-body turnover of NE without altering NE plasma levels at rest or during orthostatic challenge. There was a trend toward reduction in MHPG (an NE metabolite) and HVA concentrations following treatment.

36. A new chapter opens in anti-inflammatory treatments:The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice

36.1 Bupropion profoundly reduces TNF-α, IFN-γ, and interleukin-1β (IL-1β) in an LPS mouse model of inflammation. Mice were protected by Bupropion from what would otherwise be a lethal LPS dose. It also increased IL-10. The TNF suppression depended largely on β-adrenergic and D1 receptor agonism. Increasing Cyclic Adenosine monophosphate (cAMP) suppresses TNF.

37. The pharmacologic basis for therapeutic interest in bupropion

38. Studies of bupropion's mechanism of antidepressant activity

38.1 Bupropion reduces DA turnover in the brain.

39. Dopamine transporter-dependent induction of C-Fos in HEK cells

39.1 Bupropion increased c-Fos ≈3x in human DAT (hDAT)-expressing HEK-293 cells in vitro when administered alone, and decreased DA-induced c-Fos if coincubated with DA. DA-induced c-Fos induction involved oxidative stress, and 50% was attributable to PKC activation.

40. Bupropion: a review of its mechanism of antidepressant activity

40.1 Increases excretion of the hydroxy metabolite of Melatonin (MT), an NEergic effect.

41. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo

42. A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults

42.1 Bupropion SR up to 400mg/d reduced ADHD symptoms by 42% (vs placebo’s 24%). The percentage of ADHDers who showed a ≥30% reduction in symptoms was 76%, vs placebo’s 37%. On the clinical global impression (CGI), 52% of patients were rated either much improved or very much improved compared to 11% on placebo.

43. Bupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity

43.1 In hyperactive ADHDers, a significant positive effect was found after 3d for hyperactivity and conduct problems on the teacher’s checklist. A positive effect occurred after 28d in conduct problems and restless-impulsive behavior on parent ratings.

44. Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder

44.1 Bupropion was equally effective to Methylphenidate in treatment of ADHD.

45. Bupropion treatment of attention-deficit hyperactivity disorder in adults | American Journal of Psychiatry

46. A Placebo-Controlled Trial of Bupropion SR as an Antidote for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction

46.1 In patients on SSRIs, Bupropion SR increased sexual desire and frequency of sexual activity compared to placebo.

47. Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction

48. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?

48.1 Bupropion binds to nAChRs in resting state, reducing open probability. It speeds the desensitization process. Bupropion binds to the same site of nAChRs as Phencyclidine (PCP) and tricyclic antidepressants (TCAs).

49. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels

50. Enhanced neural response to anticipation, effort and consummation of reward and aversion during bupropion treatment

50.1 In healthy humans, 7d of 150mg/d Bupropion treatment increased ventromedial PFC (vmPFC) and caudate activity during the anticipation of reward or unpleasant taste. During the effort phase (pushing a button to achieve a pleasant taste or avoid an unpleasant taste), it increased activity in the vmPFC, striatum, dorsal anterior cingulate cortex (dACC), and primary motor cortex. During the consummatory phase, it increased activity in medial orbitofrontal cortex (mOFC), amygdala, and ventral striatum. This suggests positive effects on reward-related processing in humans.

51. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

51.1 In lighter Methamphetamine users (Using <18d in the last 30d), 12w of Bupropion SR 300mg/d reduced Methamphetamine use compared to placebo. Bupropion did not reduce Methamphetamine use in heavier users (>18d/30d use). Bupropion reduced smoking by 4.85 cigarettes/d compared to placebo.

52. A Retrospective Analysis of Two Randomized Trials of Bupropion for Methamphetamine Dependence: Suggested Guidelines for Treatment Discontinuation/Augmentation

53. Bupropion Attenuates Methamphetamine Self-Administration in Adult Male Rats

54. Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys

55. Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving

55.1 In human Methamphetamine users, 6d of Bupropion SR reduced the subjective effects of up to Methamphetamine 30mg IV (a relatively low dose for active users), with reduced ratings for “any drug effect” and “high” compared to placebo. Bupropion also reduced cue-induced Methamphetamine craving in non-treatment seeking Methamphetamine addicts. Bupropion blunted Methamphetamine-induced heart rate increases.

56. Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion . HCl--a new atypical antidepressant agent

57. Labeling in vivo of sigma receptors in mouse brain with [ 3 H]-(+)-SKF 10047: Effects of phencyclidine, (+)- and (−)-N-allylnormetazocine, and other drugs

57.1 Binds to rat σ1 with IC50 580nM-2.1μM.

58. Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study

58.1 Acute administration of 150mg Bupropion SR in humans did not produce an increase in extracellular DA in the striatum during peak levels, as measured by [11C]Raclopride positron emission tomography (PET) binding. This does not preclude the possibility of mild DAergic effects with chronic administration.

58.2 In rats, acute administration of Bupropion does robustly increase the DA level in the striatum.

~NOTE~ Likely due to differing pharmacokinetics. Bupropion is the main drug in plasma in rats, whereas it has the lowest concentration out of its metabolites at steady state in humans with functional CYP2B6).

59. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

59.1 With Bupropion SR 300mg/d for 11d (steady state), 3h after the last dose, DAT occupancy in humans averaged 26%, which was maintained for 24h.

60. Bupropion occupancy of the dopamine transporter is low during clinical treatment

60.1 In another study, Bupropion treatment of depression in humans resulted in DAT occupancy of ~14%.

61. Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors

61.1 S,S-Hydroxybupropion has an IC50 for the NET of 520nM, whereas R,R-Hydroxybupropion is completely inactive up to 10μM. Racemic Bupropion has an IC50 for the NET of 1.9μM, and racemic S,S-, R,R-Hydroxybupropion has a NET IC50 of 1.7μM. S,S-Hydroxybupropion has an α4β2 nAChR IC50 of 3.3μM, and is more potent than its R,R-enantiomer. S,S-Hydroxybupropion and Bupropion are more potent in mouse models of depression than R,R-Hydroxybupropion, and in Nicotine antagonism in vivo.

62. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor

62.1 L-Arginine (Arg) inhibited Bupropion’s antidepressant-like effects in a mouse model, and a nitric oxide (NO) synthase (NOS) inhibitor enhanced them. 10mg/kg Methylene Blue also enhanced the antidepressant-like effects of Bupropion. Sildenafil (a phosphodiesterase type 5 (PDE5) inhibitor) also inhibited Bupropion’s antidepressant effects. This suggests inhibition of the NOS/NO/cGMP pathway enhances Bupropion’s antidepressant-like effects, and conversely, stimulation of this pathway reduces its antidepressant-like effects.

63. WELLBUTRIN XL™

63.1 Bupropion reaches steady-state in 8d in humans.

63.2 Tmax for Bupropion XL is 5h for Bupropion and 7h for Hydroxybupropion, Erythrohydrobupropion and Threohydrobupropion.

63.4 Bupropion is 84% plasma protein-bound (PPB). Hydroxybupropion has similar PPB, but Threohydrobupropion’s PPB is only ~42%.

63.5 The area under the curve (AUC) for Hydroxybupropion is ~13x that of Bupropion itself at steady state.

63.6 The AUC of Erythrohydrobupropion is 1.3x that of Bupropion.

63.7 Threohydrobupropion has an AUC 7x that of Bupropion.

63.8 Bupropion and its metabolites are 87% excreted in urine, and 10% is excreted in feces. The unchanged fraction was 0.5%, indicating extensive metabolism.

63.9 Smoking status does not influence metabolism of Bupropion.

63.10 Orphenadrine, Thiotepa, Cyclophosphamide, Paroxetine, Sertraline, Norfluoxetine, Fluvoxamine, Nelfinavir, Ritonavir, and Efavirenz can inhibit or are substrates of CYP2B6 and therefore inhibit the hydroxylation of Bupropion into Hydroxybupropion.

63.11 Cimetidine 800mg increases the AUC and Cmax of Erythrohydrobupropion and Threohydrobupropion.

63.12 Bupropion is a strong CYP2D6 inhibitor, leading to 5x increases in AUC of one dose of the CYP2D6 substrate Desipramine. After chronic dosing, this effect lasts up to 7d after the last dose of Bupropion.

63.13 Bupropion may reduce alcohol (ethanol; EtOH) tolerance in some people.

63.14 At 2x and 7x the maximum human dose in rats, but not mice, there was an increase in nodular proliferative lesions of the liver. This did not result in any increase in malignancies.

63.15 Bupropion may be mutagenic according to some (but not other) in vitro data.

63.16 Bupropion is Pregnancy Category B in the US, with no animal evidence of teratogenicity.

63.17 Bupropion XL has not been directly compared to placebo in human clinical trials, but is bioequivalent to the IR and SR formulations, both of which have shown efficacy compared to placebo.

63.18 Bupropion is relatively safe in overdose, despite seizures being common.

64. Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population

64.1 In a 25w, randomized, placebo-controlled, double-blind trial, 106 opioid-dependent Cocaine abusers were treated with contingency management (CM; a program for positive reinforcement of abstinence) + either placebo or 300mg/d Bupropion. Other groups received voucher control (VC) + placebo, or VC + 300mg/d Bupropion. All patients received Methadone 60-120mg to maintain abstinence from opioids for the study duration. Bupropion or placebo was initiated at 3w. Opiate use decreased significantly, and equivalently for all groups. In the CM + Bupropion group, the proportion of Cocaine+ urine samples significantly decreased during weeks 3-13 relative to week 3 and remained low during weeks 14-25. In the CM + placebo group, Cocaine use significantly increased during weeks 3-13 relative to week 3, but then Cocaine use significantly decreased relative to the initial slope during weeks 14-25. By 25w, both of the VC groups (VC + either Bupropion or placebo), showed no significant improvement in Cocaine use. Thus, combining Bupropion with CM to treat Cocaine addiction may be a promising strategy. The early treatment effect of Bupropion implies that it may alleviate Cocaine withdrawal symptoms.

64.2 In a placebo-controlled study, 149 Cocaine abusers were treated with Bupropion for 12w. Overall, Bupropion was not different from placebo in reducing Cocaine use. However, it was significantly effective in a subset of depressed patients at decreasing Cocaine use.

64.3 Bupropion may reduce impulsivity and increase concentration. Several studies support its use in ADHD treatment.

65. A Novel, Nonbinary Evaluation of Success and Failure Reveals Bupropion Efficacy Versus Methamphetamine Dependence: Reanalysis of a Multisite Trial

65.1 Bupropion was tested for 12w for its usefulness in Methamphetamine addiction. In the Bupropion group, 20% of participants achieved ≥2w of end-of-study abstinence (EOSA), 14% achieved ≥6w EOSA, and 6% were abstinent throughout the trial. In the placebo group, 7% had ≥2w EOSA, 4% had ≥6w EOSA, and 1% were abstinent throughout. Thus, Bupropion seems to be effective for producing improvements in Methamphetamine use. The odds of achieving ≥2w EOSA in the Bupropion and placebo groups were 25.4% and 7.46%, respectively, yielding an odds ratio (OR) of 4.22. Bupropion was most effective in those who reported ≤18d/mo of baseline Methamphetamine use (OR = 7.26 for Bupropion vs placebo in this subgroup), and there was a trend-level decrease in Methamphetamine use (OR = 2.96) in users who reported 19-29d/mo baseline Methamphetamine use.

65.2 Bupropion significantly reduced the self-administration of Methamphetamine in monkeys at a dose that did not alter responding for food.

65.3 In a placebo-controlled human laboratory study, Bupropion SR 150mg 2x/d significantly reduced self-reported drug cravings in response to Methamphetamine-associated cues, and significantly reduced the reported subjective effects of Methamphetamine 15-30mg IV. Bupropion significantly attenuated the ability of IV Methamphetamine to increase heart rate, and produced a trend-level diminution of Methamphetamine-induced increases in blood pressure.

66. Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice | Journal of Pharmacy and Pharmacology | Oxford Academic

66.1 When Bupropion was administered 30min before Methamphetamine, it significantly antagonized Methamphetamine-induced stereotypic behavior in mice, but when given 5min after Methamphetamine, it significantly potentiated stereotypy.

66.2 When Bupropion 12.5-50mg/kg was administered to mice pretreated with the non-selective, irreversible monoamine oxidase inhibitor (MAOI) Pargyline at 100mg/kg, intense locomotor stimulation and stereotypy was observed.

66.3 When Bupropion was administered to mice pretreated with Clomipramine, the mice showed locomotor stimulation, head twitches, and abduction and extension of hind limbs. Unlike Clomipramine, Bupropion failed to potentiate the 5-HT-mediated behavior seen after 5-Hydroxytryptophan (5-HTP) 100mg/kg IV.

67. Bupropion Binds to Two Sites in the Torpedo Nicotinic Acetylcholine Receptor Transmembrane Domain

67.1 Bupropion acts as a noncompetitive antagonist of nAChRs. Bupropion binds to its site on nAChRs with 3x higher affinity for the desensitized state (IC50 = 1.2μM) than the resting state.

67.2 Bupropion and its analogues noncompetitively inhibit both muscle-type (fetal human α1β1γ-δ and Torpedo) and neuronal (α4β2, α3β4, α7) nAChRs in the low-to-intermediate μM range (IC50 values range from 400nM-60μM), with a rank order of potency: α3>α1~α4>α7-containing nAChRs.

67.3 In HEK-293 cells expressing α1β1ϵ-δ (adult human muscle-type) nAChRs, Bupropion inhibits the channels via 2 mechanisms mediated by binding to specific conformational states. Bupropion binding to the resting nAChR results in impaired channel opening (IC50 = 400nM), while binding to the open state results in either a slow channel block or an increase in the rate of desensitization. Bupropion binds to the desensitized state with ~2x higher affinity than to the resting (closed) state. Molecular docking and dynamics simulations predict that Bupropion binds near the middle of the nAChR ion channel (between M2-6 and M2-13). Based on in vitro studies, it was revealed that Bupropion does in fact bind in the middle (M2-9) of the Torpedo nAChR ion channel in the resting and desensitized states. In the desensitized state, Bupropion also binds in proximity to αTyr213 in αM1, a residue that resides within a Halothane/general anesthetic binding pocket.

67.4 When Torpedo nAChRs were injected into Xenopus oocytes, Bupropion reversibly inhibited ACh-induced currents with an IC50 of 300nM, similar to the reported IC50 for Bupropion inhibition of mouse muscle-type nAChRs.

67.5 αTyr213 contributes to a water-accessible general anesthetic binding pocket located at the same interface between subunits where uncharged positive and negative nAChR allosteric modulators bind more towards the middle of the transmembrane domain (TMD).

68. Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations

68.1 Bupropion is a noncompetitive inhibitor of 5-HT3A receptors. In Xenopus oocytes expressing mouse 5-HT3A and 5-HT3AB receptors, co-application of Bupropion or Hydroxybupropion with 5-HT dose-dependently inhibited 5-HT-induced currents in heteromeric 5-HT3AB receptors (IC50 = 840μM and 526μM, respectively). The corresponding IC50s for Bupropion and Hydroxybupropion for homomeric 5-HT3A receptors were 10x and 5x lower, respectively (87.1μM and 113μM). The inhibition was not use-dependent nor voltage-dependent, suggesting Bupropion is not an open channel blocker of 5-HT3 receptors. The inhibition was reversible and time-dependent. Preincubation with a low concentration of Bupropion that mimics therapeutic drug levels inhibits 5-HT-induced currents in 5-HT3A and 5-HT3AB receptors considerably. The estimated Hill slopes for both Bupropion and Hydroxybupropion for both receptors were greater than unity (1.17-1.8), suggesting the presence of multiple binding sites with a cooperative mechanism. The Hill coefficients for the 5-HT3AB receptor were ~1.4x larger for both Bupropion and Hydroxybupropion as compared with that for the 5-HT3A receptor, which may indicate a concerted conformational change or cooperativity of binding.

68.2 Bupropion, but not its metabolites, concentrates in many tissues with a brain:plasma ratio of 25:1, which results in brain concentrations of ~20μM.

68.3 Hydroxybupropion has an average therapeutic plasma concentration of ~100μM.

69. Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation

70. Bupropion-induced inhibition of α7 nicotinic acetylcholine receptors expressed in heterologous cells and neurons from dorsal raphe nucleus and hippocampus

70.1 Choline-induced currents in hippocampal interneurons were partially inhibited by 10μM Bupropion, a concentration that is clinically-attainable. Agonist-induced currents were reversibly inhibited by Bupropion at concentrations coinciding with its inhibitory potency (IC50 = 54μM) and binding affinity (Ki = 63μM) for α7 nAChRs from heterologous cells. The [3H]Imipramine competition binding and molecular docking results support a luminal location for the Bupropion binding site(s).

71.Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study - ScienceDirect

71.1 In 12 healthy controls and 16 depressed patients, the baseline DAT activity was examined by single-photon emission computed tomography (SPECT). 9/16 patients went through an additional second SPECT investigation, after 4w of Bupropion treatment. In the depressed patients, the baseline DAT striatum-occipital ratio (SOR) (1.04) was not significantly different from healthy controls. Correlation was found between baseline SOR and HAM-D score change of the Bupropion-treated patients. The average DAT occupancy due to Bupropion treatment was 20.84%. There was no significant correlation between the therapeutic efficacy and DAT occupancy. Thus, DRI actions may not significantly contribute to Bupropion’s efficacy in depressive disorders. Bupropion led to clinical improvement in 4/9 patients, whereas the clinical state of the other 5 patients remained unchanged (53% and 24% mean decrease, respectively, in HAM-D score). In the 9 patients treated with Bupropion, the SOR values were significantly higher at baseline than after 4w of Bupropion treatment. The average DAT occupancy varied within a wide range, with a mean of 20.84% (95% CI: 0-42%). On one occasion, the occupancy was negative (–39%). The DAT availability did not uniformly decrease during effective therapy. Bupropion treatment adherence was not measured, and may have contributed to variable and low occupancy.

71.2 Serum Bupropion levels correlate poorly with its cerebral concentrations. After 8d of Bupropion treatment in healthy individuals, the concentrations of Bupropion and its metabolites were found to fluctuate around the steady-state values.

72. Consistent differential effects of bupropion and mirtazapine in major depression

72.1 Bupropion excels in treating hypersomnia, weight gain, and fatigue in depression.

72.2 In the STAR*D study, Bupropion monotherapy produced greater improvement in hypersomnia than Venlafaxine in Levels 2 and 2A. Bupropion augmentation outperformed Buspirone augmentation for increased weight, increased appetite, and fatigue in Level 2.

72.3 In the CO-MED study, Escitalopram + Bupropion demonstrated complementary symptom-specific benefits.

72.4 In terms of efficacy across symptoms, the VAST-D study differentiated Bupropion monotherapy from Aripiprazole augmentation, but failed to differentiate Bupropion augmentation and Aripiprazole augmentation, even with 1522 patients, suggesting similar efficacy as augmentation agents.

🕸️ Spidikor Weavings

Listen to this tab

Blood levels are dominated by R,R-Hydroxybupropion in humans. In rats, Bupropion is the main drug present in blood, which explains typical psychostimulant effects in rodents.

S,S-Hydroxybupropion (Radafaxine) is an NDRI, with IC50s of 241nM for NE, 630nM for DA. Also an α4β2 nAChR antagonist with IC50 of 3.3μM. Bupropion and its metabolites inhibit α3β2 and α3β4 receptors with a higher affinity than α4β2.

Threohydrobupropion levels are associated with dry mouth, and it accounts for 21% of CYP2D6 inhibition.

Erythrohydrobupropion levels are associated with insomnia, and it accounts for 9% of CYP2D6 inhibition.

🤖 Overview by Gemini 3.1 Pro Deep Research

Listen to this tab

Comprehensive Pharmacological and Subjective Profile of Bupropion: Therapeutic Efficacy, Misuse Potential, and User Experiences

Introduction to Bupropion Pharmacology and Clinical Context

Bupropion represents a highly distinct entity within the modern psychopharmacological landscape. Formulated and distributed under various brand names—most notably Wellbutrin, Zyban, Aplenzin, and in combination with naltrexone as Contrave—it is an atypical antidepressant, a smoking cessation aid, and an off-label intervention for a myriad of neurobehavioral conditions.1 Unlike traditional selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), which dominate the first-line treatment protocols for major depressive disorder (MDD), Bupropion exerts virtually no clinically significant effect on serotonergic transmission.5 Instead, it functions primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI) and as a non-competitive antagonist at neuronal nicotinic acetylcholine receptors (nAChRs).7

The molecular structure of Bupropion provides critical insight into its clinical and subjective profile. Structurally, it is an aminoketone and a substituted cathinone, making it the only synthetic cathinone currently approved for medical use by the United States Food and Drug Administration (FDA).2 As a cathinone derivative, it shares a fundamental chemical backbone with amphetamines, diethylpropion, and various illicit central nervous system stimulants often colloquially referred to as "bath salts".2 This structural homology is responsible for the drug’s activating properties, its propensity to induce weight loss, its utility in treating attention-deficit/hyperactivity disorder (ADHD), and, critically, its potential for recreational misuse and dose-dependent neurological toxicity.2

The history of Bupropion's clinical deployment further underscores its complex pharmacological nature. Initially introduced to the market in 1985 as a first-generation "modern" antidepressant, it was abruptly withdrawn shortly thereafter following the discovery of an alarmingly high incidence of drug-induced seizures, particularly among patients suffering from bulimia nervosa.11 It was subsequently reformulated and reintroduced in 1989 with strictly lowered maximum daily dosage guidelines.12 Today, it remains a cornerstone therapeutic agent, yet it demands rigorous clinical oversight due to its narrow therapeutic index and the profound ways in which it alters subjective consciousness, energy metabolism, and seizure thresholds.

Pharmacokinetics and Metabolism

The subjective experience of Bupropion, including its onset, peak, and duration, is inextricably linked to its complex pharmacokinetic profile. Following oral administration, the parent compound is rapidly absorbed from the gastrointestinal tract.1 However, the parent drug is subject to extensive first-pass hepatic metabolism, primarily mediated by the cytochrome P450 2B6 (CYP2B6) isoenzyme, which converts Bupropion into its primary active metabolite, hydroxybupropion.1 Additional non-CYP-mediated metabolic pathways reduce the compound into erythrohydrobupropion and threohydrobupropion.1

These three primary metabolites are entirely biologically active. While they demonstrate a reduced potency of ≈20-50% relative to the parent compound, they accumulate in the blood plasma at significantly higher concentrations.1 Furthermore, the temporal dynamics of these metabolites govern the drug's long-term subjective effects. While the parent Bupropion molecule exhibits a relatively brief distribution half-life of 3-4 hours, hydroxybupropion boasts a half-life of ~20h, erythrohydrobupropion 33h, and threohydrobupropion up to 37h.1 The ultimate elimination half-life of the combined active systemic load is ≈21h.1

This extensive metabolic conversion and prolonged half-life dictate that Bupropion must be titrated slowly. It also explains why therapeutic efficacy is rarely immediate, typically requiring 2-4w of sustained dosing to achieve a steady-state plasma concentration and subsequent receptor downregulation necessary for clinical antidepressant action.1 Genetic polymorphisms in the CYP2B6 enzyme can significantly alter this profile; individuals who are extensive metabolizers may experience rapid peaks and subsequent crashes, while poor metabolizers may accumulate toxic levels of the parent compound, thereby increasing the risk of adverse neurological events.13

Comprehensive Dosing and Duration Guide

Bupropion’s subjective effects and safety profile vary drastically depending on the specific formulation—Immediate Release (IR), Sustained Release (SR), and Extended Release (XL)—as well as the chosen Route of Administration (RoA). To minimize the risk of dose-dependent seizures, strict clinical guidelines dictate that single oral doses should never exceed 150mg for IR, 200mg for SR, or 450mg for XL formulations.14

The following tables synthesize standard clinical prescribing limits, toxicological thresholds, and subjective reports from extensive community tracking, establishing a tiered dosing framework for the two most highly documented routes of administration: Oral (PO) and Intranasal (IN).

Oral Administration (PO) Dosing Tiers

Oral administration is the exclusive medically approved route for Bupropion. The extended and sustained-release matrices heavily influence the absorption rate, thereby modulating the peak plasma concentrations and subjective intensity.

Dosage Tier	Immediate Release (IR)	Sustained Release (SR)	Extended Release (XL)	Subjective Context and Clinical Utility
Microdose	25-50mg	37.5-75mg	N/A (Cannot be split)	Utilized entirely off-label for individuals with extreme medication sensitivity. Subjective reports indicate it provides subtle focus and anger management without triggering severe sympathetic anxiety.19
Low Dose	75mg	100mg	150mg	Serves as the standard clinical starting dose. Produces light stimulation, mild mood elevation, and a gentle increase in wakefulness.20
Regular Dose	75-125mg	150mg	300mg	The optimal therapeutic maintenance tier. Users report full NDRI benefits, robust craving suppression, steady physical energy, and cognitive clarity.4
High Dose	125-225mg	200mg	450mg	Represents the maximum approved therapeutic limits. Highly stimulating, frequently resulting in side effects such as insomnia, agitation, and fine motor tremors.14
Heavy / Risky	225-325mg	>300mg (single dose)	>450mg	Warning: Rapid escalation of dose-dependent seizure risk. Characterized by uncomfortable over-stimulation, profound anxiety, and marked physiological distress.22
Extreme	>325mg	>400mg (single dose)	>600mg	Danger: Imminent risk of generalized tonic-clonic seizures, anticholinergic-style delirium, extreme tachycardia, and potential cardiovascular collapse.7

Note: Sustained Release (SR) and Extended Release (XL) tablets rely on specialized structural matrices and coatings to control drug dissolution. Splitting, crushing, or chewing these formulations instantly destroys the release mechanism, effectively converting the entire dosage into an immediate-release bolus, which exponentially increases the risk of seizures and acute toxicity.9

Intranasal Administration (IN) Dosing Tiers

Insufflation (snorting) of crushed Bupropion tablets intentionally circumvents gastrointestinal absorption and first-pass hepatic metabolism. This delivers the parent drug directly across the highly vascularized nasal mucosa into the systemic circulation, resulting in a massive, rapid spike in dopamine transporter (DAT) occupancy.10 This route is strictly associated with illicit misuse, recreational experimentation, and profound physical harm.

Dosage Tier	Intranasal (IN) Amount	Subjective Experience and Associated Risks
Threshold	50mg	Produces barely perceptible systemic stimulation, but is characterized by an immediate, intense, and highly painful burning sensation in the nasal cavity.22
Light	50-150mg	Results in a brief, noticeable rush of energy and mild tachycardia, heavily punctuated by severe, localized facial pain and tissue irritation.9
Common	150-300mg	Yields an intense, short-lived euphoria frequently compared to cocaine. Carries a high risk of acute agitation, immediate tremors, and severe mucosal damage.9
Strong	300-900mg	Warning: Unacceptably high risk of prehospital seizures, extreme tachycardia, hypertensive crisis, and psychological panic.9
Heavy / Extreme	>900mg	Danger: Imminent and life-threatening risk of status epilepticus, cardiovascular collapse, and profound pharmacological delirium.10

Temporal Profile: Duration of Effects

The timeline of Bupropion's subjective effects is highly dependent upon the specific formulation administered and the chosen route. Because of the complex interplay between the parent compound and its long-lived metabolites, the transition between phases can be prolonged.

Oral Administration (PO) Duration (Based on Immediate Release)

Time till Onset: 40-60 minutes. The user typically notices a subtle, gradual shift in wakefulness, a lifting of brain fog, and the onset of mild physical stimulation.22 Peak serum concentrations for the IR formulation are achieved at 2 hours, SR at 3 hours, and XL at ≈5h.1
Come Up Window: 60-90 minutes. Energy levels rise steadily. Users frequently report an accompanying mild increase in heart rate, enhanced cognitive clarity, and a general brightening of mood.22
Peak: 90 minutes (specifically for IR). This phase represents the maximum subjective stimulation, acute focus, and cognitive euphoria prior to metabolic stabilization.22
Plateau: 8-12 hours. This represents the total action duration for a single active dose. The primary subjective effects level out into a sustained, functional state of alertness, emotional stability, and craving suppression.1 For XL formulations, this plateau is heavily extended across a 24-hour period.16
Comedown / Offset: 5-8 hours post-peak. Often described subjectively by users as a distinct "crash," this period is characterized by a rapid return to baseline energy levels, occasional spikes of irritability, and a sudden onset of physical fatigue.22
After-effects: 1-2d. Due to the extraordinarily long elimination half-lives of the active metabolites (up to 37 hours), residual stimulation, persistent appetite suppression, and mild insomnia can remain perceptible long after the primary mood-elevating effects have faded.1

Intranasal Administration (IN) Duration

Time till Onset: 30-120 seconds. Absorption through the highly vascularized nasal mucosa is nearly instantaneous, forcing the drug directly into the bloodstream.22
Come Up Window: 1-5 minutes. A rapid, forceful onset of intense stimulation and euphoria. This is universally accompanied by severe, excruciating nasal pain due to the caustic nature of the pill binders and the chemical itself.22
Peak: 5-20 minutes. The absolute height of the "rush." Because insufflation leads to rapid 50% DAT occupancy, this brief window is where the drug most closely mimics the pharmacological profile of illicit amphetamines or cocaine.22
Plateau: Rare or non-existent. The pharmacokinetic curve of insufflated Bupropion is highly erratic; the extreme peak is not sustained, and the experience is highly transient.22
Comedown / Total Duration: 20-180 minutes. The rapid dissipation of the parent drug from the plasma leads to an abrupt, harsh, and dysphoric comedown. Users are frequently left feeling exhausted, highly anxious, and intensely craving an immediate redose.22

Primary Subjective Benefits and Therapeutic Utility

Bupropion occupies a unique therapeutic niche due to its distinctly activating profile. For individuals suffering from specific subtypes of depression—particularly those characterized by anergia, psychomotor retardation, profound fatigue, and hypersomnia—Bupropion acts as a highly targeted, energizing intervention.31

Cognitive Euphoria, Mood Elevation, and Energy Restoration

In low to regular oral doses, Bupropion produces a mild, usually pleasant state of cognitive euphoria. While clinical literature often categorizes this simply as mood improvement or antidepressant response, subjective reports from individuals utilizing the medication provide a more nuanced picture. Users frequently describe a distinct feeling of "lightness," a sudden return of intrinsic motivation, and an underlying sense of foundational well-being.16

Traditional SSRIs are notoriously associated with emotional blunting, apathy, and a general flattening of affect. In stark contrast, Bupropion preserves, and often actively enhances, the brain's reward pathways.32 Users routinely report a renewed interest in long-abandoned hobbies, increased spontaneous sociability, and a heightened capacity to experience genuine joy.16 At clinically unremarkable therapeutic doses, certain individuals report experiencing a cognitive euphoria that is subjectively on par with mild amphetamine use, characterized by an eager desire to engage in complex physical or mental tasks and a sense that life has regained its vibrancy.22

Focus, Motivation, and Off-Label ADHD Management

Because Bupropion elevates synaptic concentrations of dopamine and norepinephrine—the precise neurotransmitters targeted by classic central nervous system stimulants like methylphenidate and dextroamphetamine—it is frequently and successfully prescribed off-label for the management of Attention-Deficit/Hyperactivity Disorder (ADHD).1

Subjective experiences highlight significant motivation enhancement. Users describe becoming more talkative, displaying an increased interest in mundane or repetitive tasks, and experiencing a profound "slowing down" of chaotic, racing thoughts.22 The focus provided by Bupropion is generally described in community reports as "smoother," more subtle, and less forceful than that of traditional stimulants. It allows for increased executive function and working memory capacity without the intense, sometimes uncomfortable "hyper-focus" or the profound, debilitating afternoon crashes strictly associated with amphetamine derivatives.22

Furthermore, users specifically note that Bupropion provides an "extra half-second" of processing time, allowing them to pause, evaluate their impulses, and make conscious choices rather than reacting reflexively.36 However, indirect clinical comparisons indicate that Bupropion is generally less efficacious than pure amphetamines for severe, hyperactive-type ADHD, serving rather as a highly effective second-line or adjunctive treatment. It is particularly valuable for individuals who suffer from comorbid substance abuse disorders, or those who simply cannot tolerate the severe cardiovascular stimulation or anxiety induced by standard ADHD medications.14

Craving Suppression and Addiction Management

Bupropion's non-competitive antagonism at nicotinic acetylcholine receptors (nAChRs), combined with its dopaminergic reward-pathway stimulation, makes it a highly effective tool for smoking cessation. It was famously marketed specifically for this purpose under the brand name Zyban.14

Subjective user reports emphasize a fascinating mechanism regarding its anti-addiction properties: the drug does not necessarily induce a physical aversion or sickness when smoking, but rather, it systematically dismantles the psychological craving and diminishes the reward or "buzz" typically received from the nicotine.22 Users report that the habitual desire to smoke simply falls away, with the urge becoming easily ignorable or entirely forgotten.22

Beyond nicotine, this mechanism of reward-pathway recalibration has shown profound efficacy in reducing cravings for other high-dopamine behaviors. Clinical reports and subjective experiences indicate that Bupropion effectively mitigates the urge for binge eating, compulsive spending, and, in some experimental clinical contexts, it has been utilized to manage cravings associated with cocaine and Methamphetamine dependence.26 By providing a steady baseline of dopamine, the brain is less desperate to seek out sharp, exogenous dopaminergic spikes.

Reversal of SSRI-Induced Sexual Dysfunction

A highly notable and celebrated subjective benefit of Bupropion is its complete lack of sexual side effects. SSRIs are notorious for causing devastating sexual dysfunction, including anorgasmia, severely decreased libido, and erectile dysfunction, which frequently leads to patient non-compliance. Bupropion is completely devoid of these effects. In fact, it is frequently prescribed specifically to reverse the sexual dysfunction induced by concurrent SSRI therapy.14 Users routinely report a marked, sometimes dramatic increase in libido, heightened tactile sensitivity, and the restoration of sexual satisfaction shortly after initiating Bupropion therapy or adding it as an adjunct to an existing SSRI regimen.22

Weight Loss and Metabolic Enhancement

Unlike serotonergic agents, which are frequently linked to weight gain and carbohydrate cravings, Bupropion is associated with weight neutrality and, quite often, clinically significant weight loss.40 By elevating dopamine and norepinephrine, Bupropion modulates the hypothalamic appetite centers, effectively lowering hunger signals and promoting early satiety.40 Furthermore, the increased sympathetic nervous activity nudges the resting metabolic rate upward, creating a mild thermogenic effect that favors fat loss.42

Subjectively, users frequently report a total loss of interest in food, describing a phenomenon where they must consciously remind themselves to eat, as the biological drive of hunger is profoundly suppressed.20 While highly beneficial for obesity treatment—especially when combined with naltrexone in the formulation Contrave, which further blocks opioid-mediated food rewards—this intense appetite suppression requires monitoring to prevent unhealthy caloric deficits in vulnerable patients.3

The "Honeymoon Phase" and Long-Term Trajectory

A widely reported, almost universal phenomenon among Bupropion users is the "honeymoon phase." This period, typically spanning the first 1-2w of treatment, is characterized by intense physical energy, profound mood elevation, mild euphoria, extreme sociability, and what feels like an absolute remission of all depressive or ADHD symptoms.21 During this phase, the sudden, unaccustomed influx of dopamine and norepinephrine closely mimics a low-grade stimulant high, occasionally bordering on hypomania.43

However, this phase is invariably transient. The human brain is highly adaptive; as it detects the sustained, artificial elevation of these neurotransmitters, robust homeostatic mechanisms engage. This leads to the systematic downregulation of postsynaptic dopamine receptors.44

Subjectively, users often feel a sense of profound disappointment as the honeymoon phase ends. They frequently report that the medication has "stopped working," as the initial euphoric rush fades into a normalized, baseline state.44 This plateau is a critical, highly misunderstood juncture in Bupropion therapy. While the overt, recreational-style stimulation subsides, the clinical antidepressant and anti-craving effects are typically sustained.40

If users or clinicians mistakenly attempt to chase the initial euphoria by prematurely escalating the dose from 150-300mg or 450mg, it rarely recaptures the magic. Instead, it leads to severe anxiety, intractable insomnia, emotional blunting, and an unacceptably increased risk of seizures.21 Successful long-term management requires accepting the plateau, recognizing that a constant state of euphoria is not the clinical goal, and utilizing the stabilized, underlying energy to implement permanent behavioral and lifestyle changes.40

Subjective Side Effects and Adverse Reactions

While Bupropion elegantly sidesteps many of the adverse effects associated with serotonergic drugs, its adrenergic and dopaminergic nature introduces a distinct, often highly uncomfortable profile of adverse reactions.

Anxiety, Agitation, and the Sympathetic Overdrive

The most frequently cited limiting factor for Bupropion therapy is its propensity to induce, unmask, or severely exacerbate anxiety.12 The sustained increase in norepinephrine tone can lock the user into a persistent "fight or flight" physiological state.33 Users report profound jitteriness, a racing heart (tachycardia), hypervigilance, and a creeping sense of impending doom or panic.39 For individuals whose depression is secondary to, or comorbid with, a primary anxiety disorder, Bupropion can make their psychiatric presentation significantly worse.31

Emotional Dysregulation and Anger

Paradoxically for an antidepressant, Bupropion can induce severe emotional dysregulation in susceptible individuals. Subjective reports heavily detail the sudden onset of abrupt anger loops, extreme irritability, a "short fuse," and uncontrollable bouts of crying over minor inconveniences.21 Users describe feeling highly agitated, easily provoked, and possessing intrusive thoughts of frustration.47

Conversely, some users note a shift toward profound emotional blunting or coldness. In these cases, empathy is drastically diminished, the individual becomes hyper-logical, and social interactions feel mechanical and devoid of warmth.19 Furthermore, in patients with undiagnosed or underlying bipolar spectrum disorders, Bupropion carries a significant risk of inducing true manic or hypomanic episodes, characterized by racing thoughts, reckless behavior, decreased need for sleep, and grandiosity.18

Cognitive Deficits: Brain Fog and Aphasia

A lesser-known but highly distressing side effect reported by a specific subset of users is the induction of severe cognitive deficits, particularly regarding working memory and verbal recall.48 Despite its use as an ADHD medication, some users report that Bupropion drastically impairs their ability to find the right words during conversation, leading to a form of expressive aphasia.48 Users describe feeling as though their IQ has dropped, experiencing profound brain fog, and struggling to articulate complex thoughts—a side effect that can be devastating for individuals in high-communication professions, such as sales or teaching.48 These cognitive impairments typically resolve fully upon discontinuation of the medication.48

Physical Side Effects: Insomnia, Tinnitus, and Hyperhidrosis

The peripheral sympathetic activation caused by Bupropion leads to several pervasive physical side effects:

Insomnia: Occurring in up to 40% of patients, the stimulating nature of the drug makes falling and staying asleep incredibly difficult. This is especially true if extended-release (XL) formulations are taken too late in the day, or if the dosage is too high.14
Tinnitus: A frequently reported, highly distressing side effect is a constant, high-pitched ringing in the ears. In some alarming community reports, users state that this drug-induced tinnitus persists permanently, long after the medication has been discontinued.18
Tremors and Sweating: Fine motor tremors in the hands, muscle tension, jaw clenching, and excessive hyperhidrosis (sweating) are common, reflecting a state of sympathetic nervous system overdrive.14
Gastrointestinal and Sensory Issues: Severe dry mouth (xerostomia), constipation, acid reflux (GERD), and changes in the sense of taste are frequently reported during the initial weeks of treatment.1

Dream Potentiation and Sleep Architecture

Bupropion has a profound, highly specific impact on sleep architecture and the nature of dreaming. Users report wild, incredibly vivid, realistic, and highly immersive dreams. These dreams often diverge from the abstract nature of normal dreaming, taking on linear, adventure-like narratives that feel fully real to the dreamer.22

Due to the drug's nAChR antagonism and high norepinephrine activity, the recall of these dreams upon waking is significantly enhanced.22 However, this potentiation is a double-edged sword; it can easily cross into the territory of vivid night terrors. Users frequently report waking up feeling entirely exhausted, as if time had expanded and they had lived for days or weeks within the stressful dream state, completely negating the restorative purpose of sleep.22

Toxicity, High-Dose Effects, and Pharmacological Delirium

Bupropion possesses an incredibly narrow therapeutic index regarding neurological toxicity. Dosages exceeding the recommended 450mg//d radically alter the drug's safety profile, shifting it from a therapeutic agent to a dangerous neurotoxin.14

Dose-Dependent Seizures

The absolute hallmark of Bupropion toxicity is the induction of generalized tonic-clonic (grand mal) seizures.9 Bupropion lowers the seizure threshold in a strictly dose-dependent manner. At therapeutic doses of the immediate-release (IR) formulation (up to 450mg/d), the seizure incidence is ~0.4%.23 However, when dosages climb to between 600-900mg, the risk increases almost tenfold to an alarming 2.8%.23

The sustained-release (SR) and extended-release (XL) formulations were specifically engineered by pharmaceutical companies to blunt the peak plasma concentrations of the drug, which successfully reduced the seizure incidence to ~0.1% at the target dose of 300mg.23 In overdose scenarios—where the median ingested dose associated with seizures is 4.4g—seizures are nearly guaranteed.7 Overdose literature indicates that 68-77% of Bupropion-induced seizures occur within 4 hours of ingestion for IR formulations, but onset can be dangerously delayed up to 24 hours in patients who ingest extended-release preparations, requiring prolonged medical observation.7

Anticholinergic Delirium and Hallucinosis

At toxic, heavy, or massive recreational doses, Bupropion’s non-competitive antagonism of nicotinic acetylcholine receptors (nAChRs) becomes highly pronounced. This induces a state of true pharmacological delirium.22

Unlike the delirium induced by classic anticholinergics (such as diphenhydramine/Benadryl or datura)—which is often accompanied by heavy physical sedation and lethargy—Bupropion delirium is uniquely distressing and physically dangerous. The profound NDRI activity keeps the user forcefully awake, highly stimulated, and physically agitated while their mind completely fragments.22

Cognitive effects at this toxic stage include extreme paranoia, violent disinhibition, and a complete loss of touch with reality (delusions).22 Visual and auditory hallucinations manifest intensely. Users report terrifying external hallucinations such as seeing "shadow people," environments drifting or melting, enhanced pattern recognition, and persistent visual tracers.22 Auditory hallucinations are common, where sounds become physically painful or manifest as non-existent voices conversing with the user.22 Tactile hallucinations, such as formication (the sensation of insects crawling on or under the skin), are also prevalent, closely mimicking the amphetamine psychosis seen in severe Methamphetamine toxicity.22 This state is physically exhausting, mentally terrifying, and requires immediate emergency medical intervention, usually involving high doses of intravenous benzodiazepines (e.g., lorazepam) to manage the agitation and prevent status epilepticus.7

Cardiovascular and Systemic Toxicity

Massive overdoses do not only target the brain; they can lead to life-threatening cardiovascular emergencies. Sinus tachycardia is nearly universal in overdose. However, severe toxicity can induce widening of the QRS complex, profound QTc prolongation, ventricular dysrhythmias, cardiogenic shock, and ultimately, cardiac arrest.5 Case reports have also documented severe secondary complications resulting from the extreme physiological stress of the overdose, such as delayed rhabdomyolysis (muscle breakdown leading to kidney failure) and permanent hypoxic encephalopathy following Bupropion-induced status epilepticus.5

Alternative Routes of Administration and Abuse Potential

Despite its clinical classification as a relatively safe antidepressant with a low theoretical abuse liability, Bupropion's chemical identity as a synthetic cathinone has led to widespread, highly dangerous misuse. This phenomenon is particularly prevalent in environments where traditional illicit stimulants are inaccessible, such as within correctional facilities, leading to its moniker as the "poor man's cocaine".2

Insufflation (Intranasal) Abuse

Crushing and snorting Bupropion pills—referred to on the street, in internet forums, and in prisons by slang terms such as "welbys," "wellies," "dubs," or "barnies"—is the most common method of misuse.2 Because it is a cheap, unscheduled prescription drug, massive quantities can be acquired for very little money (e.g., 30 pills for $100), making it an attractive target for desperate users.54

Mechanism and Effects: By bypassing the gastrointestinal tract and avoiding first-pass hepatic metabolism entirely, insufflation delivers the parent drug directly across the highly vascularized nasal mucosa and into the systemic circulation.9 This extremely rapid absorption results in a sudden, massive spike in DAT transporter occupancy in the brain—achieving the 50% occupancy threshold required for drug reinforcement and reward conditioning.26 Unlike oral administration, which is slow and provides no discernible "rush," insufflation yields an immediate, intense euphoria and a powerful stimulant high. Users directly compare this sensation to cocaine or amphetamine, albeit often reported as slightly less intense, shorter-lived, and noticeably "dirtier".7

Severe Physical Toll and Risks: The physical damage caused by insufflating Bupropion is immense. The tablets are not designed for mucosal absorption; they contain caustic binders, fillers, and the chemical itself is highly irritating. Users universally report an excruciating, blinding burning sensation upon insufflation, frequently likened to the pain of "snorting glass".29 Chronic insufflation rapidly leads to severe damage to the delicate nasal membranes, chronic epistaxis (nosebleeds), throat damage, and eventual septal perforation.27 In extreme cases, inhaling the powder into the lungs has resulted in diffuse alveolar hemorrhage, a life-threatening condition requiring intensive care and high-dose corticosteroid treatment.57

Furthermore, insufflation carries an exceptionally high, unpredictable risk of inducing sudden seizures and extreme tachycardia.9 Crushing the pill destroys any sustained-release properties, hitting the brain with an immediate toxic dose. Toxicological data reveals that seizures frequently occur within 15min-8h post-insufflation, often without any prodromal warning signs, making it a highly dangerous and potentially lethal recreational practice.9

Intravenous (IV) Injection

Intravenous injection of Bupropion represents the absolute most hazardous route of abuse. When users attempt to crush the pills, dissolve them in water, and inject the resulting slurry, they introduce a host of insoluble binders, wax matrices, and fillers directly into their bloodstream.2

Consequences: The effects are physically devastating. IV Bupropion abuse is closely associated with severe vascular complications. The caustic nature of the drug and the physical blockage caused by the fillers lead to venous insufficiency, arterial occlusion, severe tissue ischemia, and localized necrosis (the literal death of tissue cells at the injection site).2 Furthermore, it carries an imminent risk of systemic infection, massive abscess formation, and immediate, catastrophic cardiac arrest or refractory status epilepticus.5

Sublingual (SL) Administration

Though less common than insufflation, sublingual administration involves placing crushed pieces of the tablet under the tongue and allowing them to dissolve.60 Similar to intranasal use, this route bypasses first-pass hepatic metabolism, allowing the drug to enter the bloodstream directly through the sublingual mucosal tissues.62

Case reports describe users taking fractions of a tablet (e.g., 50mg) sublingually to achieve brief, 3-4h windows of euphoria, extreme sociability, and disinhibition.62 Users report using this method specifically to overcome social anxiety in specific situations.62 However, this method carries the exact same unpredictability regarding massive plasma concentration spikes, rapidly leading to severe palpitations, hypertension, and highly elevated seizure risks.62

Sub-Therapeutic Dosing and the "Microdosing" Phenomenon

An emerging, highly discussed trend among patients who are exceptionally sensitive to psychotropic medications is the intentional use of sub-therapeutic doses, colloquially referred to within community forums as "microdosing".19 The standard clinical floor for Bupropion is generally considered to be 150mg XL or 100mg SR.4 However, for a subset of individuals, these starting doses provoke intolerable anxiety, hyper-stimulation, emotional blunting, or severe insomnia, leading to rapid discontinuation of the drug.

Methodology: Because sustained and extended-release matrices (SR and XL) rely on specialized physical coatings and chemical matrices to control the slow release of the drug, they cannot be split, cut, or crushed without entirely destroying the release mechanism and risking a sudden, toxic overdose.9 Therefore, sub-therapeutic dosing is exclusively achieved by splitting Immediate Release (IR) tablets (e.g., carefully cutting a 75mg IR or 100mg IR pill into halves or quarters) or by utilizing specialized compounding pharmacies to create custom low-dose capsules.20

Subjective Utility and Benefits: Users employing daily doses ranging from 25-75mg report that these specific "microdoses" provide sufficient dopaminergic and noradrenergic support to gently lift brain fog, increase baseline physical energy, and stabilize mood.19 Crucially, they achieve these benefits without triggering the intense peripheral nervous system activation that causes the sweating, severe tremors, and panic attacks seen at the 150mg or 300mg levels.19

For some individuals dealing with mild ADHD or persistent anger rumination, a <75mg dose acts as a subtle emotional buffer. It effectively breaks the loop of irritability and frustration while allowing the patient to maintain their core personality, entirely avoiding the mechanical, emotional blunting and aphasia that they experienced at higher therapeutic doses.19

Critical Interactions and Contraindications

Bupropion interacts dangerously with several specific substances and physiological conditions, requiring strict clinical vigilance.

Alcohol, Benzodiazepines, and the Seizure Threshold

The interaction between Bupropion and alcohol is particularly hazardous and highly deceptive. Alcohol is a central nervous system depressant, while Bupropion acts as a stimulant.65 Combining them masks the subjective intoxicating effects of the alcohol, leading to impaired judgment and dangerous overconsumption, as the user does not feel as drunk as they actually are.65

More critically, Bupropion inherently lowers the seizure threshold. If an individual with a history of heavy alcohol or benzodiazepine use suddenly ceases or drastically reduces their consumption while taking Bupropion, the resulting physiological withdrawal further drastically lowers the seizure threshold. This creates a "perfect storm" for grand mal seizures and status epilepticus.11 Users who mix the two substances frequently report experiencing sudden, severe "blackouts" (anterograde amnesia, where periods of time are completely lost), extreme vertigo, and rapid onset of severe nausea and vomiting.65 Sudden cessation of alcohol while on this drug can be fatal.65

Monoamine Oxidase Inhibitors (MAOIs)

Bupropion is strictly and universally contraindicated with all Monoamine Oxidase Inhibitors (MAOIs), such as phenelzine, selegiline, isocarboxazid, and linezolid.17 Co-administration completely prevents the enzymatic breakdown of the artificially elevated dopamine and norepinephrine. This synergy leads to a catastrophic hypertensive crisis, sudden high body temperature, severe convulsions, and potential death. A strict minimum 14d washout period is absolutely required when switching a patient between Bupropion and any MAOI.4

The Daily Comedown, Long-Term Withdrawal, and Discontinuation

The temporal dynamics of Bupropion dictate that users must manage both daily fluctuations in plasma levels and the eventual discontinuation of the drug.

The Daily "Crash"

Similar to amphetamine-based ADHD medications, users of immediate-release (IR) and sustained-release (SR) Bupropion often experience a distinct, highly noticeable "crash" as the drug's plasma levels rapidly drop in the late afternoon or evening.27 This offset period is marked by sudden, profound physical fatigue, a return of mental fog, and a sharp, unpredictable spike in irritability, sadness, or anxiety.19 The transition from a highly stimulated, dopaminergic state back to baseline can cause temporary but severe dysphoria. This daily roller-coaster is precisely why formulations like Wellbutrin XL (extended-release) were developed—to smooth out the pharmacokinetic curve and provide a gentle, imperceptible 24-hour taper that prevents the afternoon crash.14

The Withdrawal Timeline

When long-term Bupropion therapy is discontinued, users may experience a distinct withdrawal phase. Because Bupropion does not influence serotonin, users rarely experience the severe, debilitating "brain zaps" (electrical shock sensations), profound vertigo, or severe flu-like symptoms universally associated with SSRI/SNRI discontinuation (e.g., coming off venlafaxine or paroxetine).6 However, the sudden absence of dopamine and norepinephrine reuptake inhibition leaves the central nervous system temporarily depleted, and the brain requires time to upregulate its receptor sensitivities back to baseline.67

Days 1-3: Because the drug and its active metabolites possess such long half-lives (up to 37 hours), it takes several days for the systemic load to clear. Initial symptoms emerge very subtly. Users report the creeping onset of physical lethargy, returning brain fog, and a general feeling of being emotionally flat or unmotivated.6
Days 4-7 (The Peak Phase): This is when withdrawal symptoms reach their maximum intensity. The subjective emotional experience is characterized by intense irritability, volatile mood swings, unpredictable bouts of anger, and heightened rebound anxiety.51 Physical symptoms may mirror a mild viral illness, including dull, persistent headaches, muscle aches, excessive sweating, and mild chills.51 Sleep architecture becomes highly disrupted; users may experience severe rebound insomnia, or conversely, excessive hypersomnia accompanied by incredibly vivid, exhausting dreams.67
Weeks 2-4 (Resolution): Physical symptoms such as headaches and sweating rapidly dissipate. Cognitive and emotional symptoms, such as anhedonia, irritability, and poor concentration, slowly resolve as endogenous dopamine and norepinephrine levels stabilize.51 By 28d, the vast majority of users report that withdrawal symptoms have entirely ceased.68

Differentiating Withdrawal from Relapse

A significant clinical challenge during the discontinuation of Bupropion is distinguishing between temporary withdrawal symptoms and a genuine relapse of the underlying psychiatric condition.6

Withdrawal symptoms are acute, feature physical manifestations (such as dizziness, headaches, flu-like aches, and sudden sweating), and follow a specific chronological curve—peaking within the first 4-7d before gradually and consistently subsiding.67 They are a physiological reaction to the absence of the chemical.

Conversely, if symptoms such as profound anhedonia, deep depression, crippling fatigue, or severe ADHD manifestations slowly build over several weeks, do not feature the physical hallmarks of withdrawal, and remain static or worsen beyond the 1mo mark, it strongly indicates a relapse of the baseline pathology. This requires the patient and clinician to reevaluate the treatment plan and potentially reinstate pharmacological support.6

Works cited

Bupropion - StatPearls - NCBI Bookshelf - NIH, accessed March 6, 2026, https://www.ncbi.nlm.nih.gov/books/NBK470212/
Bupropion toxicity with unintentional exposure or abuse, accessed March 6, 2026, https://bcmj.org/bccdc/bupropion-toxicity-unintentional-exposure-or-abuse-more-common-you-think
Naltrexone SR/Bupropion SR (Contrave): A New Approach to ... - PMC, accessed March 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3138366/
Bupropion (oral route) - Side effects & dosage - Mayo Clinic, accessed March 6, 2026, https://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/description/drg-20062478
Severe Bupropion Overdose Resulting in Cardiac Arrest, Delayed, accessed March 6, 2026, https://www.mdpi.com/2075-1729/15/12/1918
Wellbutrin (Bupropion) Withdrawal Symptoms and Effects - WebMD, accessed March 6, 2026, https://www.webmd.com/depression/wellbutrin-withdrawal
Bupropion abuse and overdose - PMC - NIH, accessed March 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4162783/
Bupropion: Skinny Happy Drug or Toxicologic Menace?, accessed March 6, 2026, https://www.emra.org/emresident/article/bupropion-skinny-happy-drug-or-toxicologic-menace
Bupropion: The “Poor Man's Cocaine”? A Case Report | ACOEP RSO, accessed March 6, 2026, https://acoep-rso.org/the-fast-track/bupropion-the-poor-mans-cocaine-a-case-report/
The ToxIC NOSE (Novel Opioid and Stimulant Exposure) - ACMT, accessed March 6, 2026, https://www.acmt.net/wp-content/uploads/2023/01/NOSE-9-Bupropion-Stimulant-Abuse-FINAL-TO-POST.pdf
Bupropion Hydrochloride Extended-Release Tablets, USP, accessed March 6, 2026, https://bauschhealth.ca/wp-content/uploads/2021/11/Wellbutrin-XL-PM-E-2021-06-10.pdf
3 Myths About Bupropion | Psychiatric Times, accessed March 6, 2026, https://www.psychiatrictimes.com/view/3-myths-about-bupropion
Steady-State Clinical Pharmacokinetics of Bupropion Extended, accessed March 6, 2026, https://www.researchgate.net/publication/6662767_Steady-State_Clinical_Pharmacokinetics_of_Bupropion_Extended-Release_in_Youths
Bupropion Guide: Pharmacology, Indications, Dosing Guidelines, accessed March 6, 2026, https://psychopharmacologyinstitute.com/publication/bupropion-guide-pharmacology-indications-dosing-guidelines-and-adverse-effects-2920/
Bupropion - Prescriber's Guide, accessed March 6, 2026, https://www.cambridge.org/core/books/prescribers-guide/bupropion/EB8BBF640718A7FAE668D4E669CF37E5
How Long For Wellbutrin (Bupropion) to Work? 5 Signs it's Working, accessed March 6, 2026, https://www.talkiatry.com/blog/how-long-for-wellbutrin-to-work
WELLBUTRIN® (bupropion hydrochloride) tablets, for oral use, accessed March 6, 2026, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018644s052lbl.pdf
Bupropion: Uses, Dosage, Side Effects - Drugs.com, accessed March 6, 2026, https://www.drugs.com/bupropion.html
Bupropion IR 75 mg vs 100 mg. Is there a noticeable difference for, accessed March 6, 2026, https://www.reddit.com/r/ADHD/comments/1pmkift/bupropion_ir_75_mg_vs_100_mg_is_there_a/
Has anyone tried doses lower than 75mg? : r/bupropion - Reddit, accessed March 6, 2026, https://www.reddit.com/r/bupropion/comments/1mvbp1t/has_anyone_tried_doses_lower_than_75mg/
Thoughts or experiences on low dosage Wellbutrin being ... - Reddit, accessed March 6, 2026, https://www.reddit.com/r/bupropion/comments/18kp935/thoughts_or_experiences_on_low_dosage_wellbutrin/
Talk:Bupropion - PsychonautWiki, accessed March 6, 2026, https://psychonautwiki.org/wiki/Talk:Bupropion
A Case Report of Seizure Induced by Bupropion Nasal Insufflation, accessed March 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC1894833/
Wellbutrin Side Effects, Symptoms of Abuse, and Addiction Treatment, accessed March 6, 2026, https://drugabuse.com/stimulants/wellbutrin/
Bupropion - Wikipedia, accessed March 6, 2026, https://en.wikipedia.org/wiki/Bupropion
(PDF) Bupropion Diversion and Misuse in the Correctional Facility, accessed March 6, 2026, https://www.researchgate.net/publication/240309918_Bupropion_Diversion_and_Misuse_in_the_Correctional_Facility
Examining symptoms of stimulant misuse and community support, accessed March 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10755072/
Concerta crash: What it is and how to prevent symptoms, accessed March 6, 2026, https://www.medicalnewstoday.com/articles/325673
Safer snorting information - CATIE.ca, accessed March 6, 2026, https://www.catie.ca/safer-snorting-information
Intranasal Bupropion Abuse Case Report | Request PDF, accessed March 6, 2026, https://www.researchgate.net/publication/235646714_Intranasal_Bupropion_Abuse_Case_Report
What do you normally prescribe for anergic depression ... - Reddit, accessed March 6, 2026, https://www.reddit.com/r/Psychiatry/comments/1joyx0b/what_do_you_normally_prescribe_for_anergic/
Bupropion Addiction | There's No Need to Struggle, accessed March 6, 2026, https://www.alternativetomeds.com/blog/bupropion-addiction/
Low Brain Norepinephrine Levels in ME/CFS and Long COVID Pt. II, accessed March 6, 2026, https://www.healthrising.org/blog/2025/11/16/brain-norepinephrine-chatgpt-treatment-chronic-fatigue-long-covid/
Bupropion for ADHD Reviews (Page 2) - Drugs.com, accessed March 6, 2026, https://www.drugs.com/comments/bupropion/for-attention-deficit-disorder.html?page=2
Erowid Bupropion (Wellbutrin) Vault, accessed March 6, 2026, https://www.erowid.org/pharms/bupropion/
Have non-stim meds helped you? : r/adhdwomen - Reddit, accessed March 6, 2026, https://www.reddit.com/r/adhdwomen/comments/1dxf134/have_nonstim_meds_helped_you/
Wellbutrin + stimulants safety? : r/medicine - Reddit, accessed March 6, 2026, https://www.reddit.com/r/medicine/comments/176eqit/wellbutrin_stimulants_safety/
Alcohol and Other Drugs: A Handbook for Health Professionals, accessed March 6, 2026, https://nceta.flinders.edu.au/application/files/9216/0156/0163/EN199.pdf
Does Bupropion cause Depression? Read What Users Report, accessed March 6, 2026, https://www.drugs.com/comments/bupropion/sfx-depression.html
Bupropion for Weight Loss: Efficacy, Mechanisms & Clinical Evidence, accessed March 6, 2026, https://shanghaiarchivesofpsychiatry.org/bupropion-for-weight-loss/
15 Years of Clinical Experience With Bupropion HCl - PMC - NIH, accessed March 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC1163271/
Wellbutrin Weight Loss: Science, Effects & Timeline - BodySpec, accessed March 6, 2026, https://www.bodyspec.com/blog/post/wellbutrin_weight_loss_science_effects_timeline
75 mg — effective or no? : r/bupropion - Reddit, accessed March 6, 2026, https://www.reddit.com/r/bupropion/comments/1av545b/75_mg_effective_or_no/
Thoughts on Bupropion/Wellbutrin “no longer working” for some of, accessed March 6, 2026, https://www.reddit.com/r/bupropion/comments/wwraw0/thoughts_on_bupropionwellbutrin_no_longer_working/
Any experience with sub-75 mg doses? : r/bupropion - Reddit, accessed March 6, 2026, https://www.reddit.com/r/bupropion/comments/fc5a1w/any_experience_with_sub75_mg_doses/
Comparison of Combined Bupropion and Naltrexone Therapy for, accessed March 6, 2026, https://academic.oup.com/jcem/article/94/12/4898/2596850
Bupropion (Wellbutrin) week one side effects, considering quitting, accessed March 6, 2026, https://www.reddit.com/r/ADHD/comments/ydcxsg/bupropion_wellbutrin_week_one_side_effects/
Do yall know anything that works for adhd? : r/Nootropics - Reddit, accessed March 6, 2026, https://www.reddit.com/r/Nootropics/comments/1l6ryu1/do_yall_know_anything_that_works_for_adhd/
What is your experience with Bupropion?" : r/ADHD - Reddit, accessed March 6, 2026, https://www.reddit.com/r/ADHD/comments/11dijg2/what_is_your_experience_with_bupropion/
Documentating Quitting Antidepressants (Wellbutrin XL 300mg) after, accessed March 6, 2026, https://www.bluelight.org/community/threads/documentating-quitting-antidepressants-wellbutrin-xl-300mg-after-over-2-years.913153/
Wellbutrin Withdrawal | Recovery Centers of America, accessed March 6, 2026, https://recoverycentersofamerica.com/blogs/wellbutrin-withdrawal/
Meth Withdrawal Symptoms | Detox Timeline - Recovery By The Sea, accessed March 6, 2026, https://rbsrehab.com/meth-withdrawal-symptoms/
Bupropion Toxicity - Emergency Medicine Residents' Association, accessed March 6, 2026, https://www.emra.org/emresident/article/bupropion-toxicity
Poor Man's Cocaine: The High Price of Cheap Drugs, accessed March 6, 2026, https://designforchangerecovery.com/blog/poor-mans-cocaine-cheap-drugs-have-a-high-price/
Patient has been abusing bupropion XL : r/pharmacy - Reddit, accessed March 6, 2026, https://www.reddit.com/r/pharmacy/comments/15cs6dk/patient_has_been_abusing_bupropion_xl/
bupropion sustained release: Topics by Science.gov, accessed March 6, 2026, https://www.science.gov/topicpages/b/bupropion+sustained+release
Episode 974: It Turns Out Snorting Bupropion Is a Really Bad Idea, accessed March 6, 2026, https://pharmacyjoe.com/episode974/
Intravenous Administration and Abuse of Bupropion: A Case Report, accessed March 6, 2026, https://www.researchgate.net/publication/263290440_Intravenous_Administration_and_Abuse_of_Bupropion_A_Case_Report_and_a_Review_of_the_Literature
Bupropion overdose: Suicide attempt or recreational disaster? - ACEP, accessed March 6, 2026, https://www.acep.org/toxicology/newsroom/mar2019/bupropion-overdose-suicide-attempt-or-recreational-disaster
Buprenorphine Sublingual and Buccal (opioid dependence), accessed March 6, 2026, https://medlineplus.gov/druginfo/meds/a605002.html
Buprenorphine Sublingual Tablets: Uses & Side Effects, accessed March 6, 2026, https://my.clevelandclinic.org/health/drugs/19451-buprenorphine-sublingual-tablets
Girls Like to Chat with me If There is a Piece of Bupropion Under My, accessed March 6, 2026, https://www.researchgate.net/publication/266736933_Girls_Like_to_Chat_with_me_If_There_is_a_Piece_of_Bupropion_Under_My_Tongue
Looking to "microdose" 10 mg, Wellbutrin was a miracle drug for me, accessed March 6, 2026, https://www.reddit.com/r/Wellbutrin_Bupropion/comments/1oc0b5x/looking_to_microdose_10_mg_wellbutrin_was_a/
Buproprion to help with focus. : r/MultipleSclerosis - Reddit, accessed March 6, 2026, https://www.reddit.com/r/MultipleSclerosis/comments/1heg091/buproprion_to_help_with_focus/
Wellbutrin and Alcohol: Drinking Alcohol While Taking Bupropion?, accessed March 6, 2026, https://thehouseoflife.com/wellbutrin-and-alcohol/
Conflicted feelings... and I miss Adderall sometimes. - TotallyADD, accessed March 6, 2026, https://totallyadd.com/forums/forums/topic/conflicted-feelings-and-i-miss-adderall-sometimes/
What is Wellbutrin Withdrawal: Symptoms, Causes & Treatment, accessed March 6, 2026, https://hopeharborwellness.com/wellbutrin-withdrawal/
Wellbutrin® Withdrawal Symptoms & Timeline - Recovery Unplugged, accessed March 6, 2026, https://www.recoveryunplugged.com/wellbutrin-withdrawal-symptoms-timeline/

🤖 Bupropion

Comprehensive Pharmacological Monograph: Bupropion

🗂️ Pharmacological Taxonomy

Chemical Superclass: Alkaloids and derivatives

Chemical Class / Backbone: Aminoketone / Substituted Cathinone

Therapeutic / Pharmacological Category: Atypical Antidepressant / Smoking Cessation Aid

Primary Mechanism of Action: NDRI (Norepinephrine-Dopamine Reuptake Inhibitor) / nAChR Antagonist

Bupropion

Level 1: Chemical Architecture & Structure-Activity Relationship (SAR)

Bupropion represents a highly distinct entity within the psychopharmacological landscape. Formally designated by the International Union of Pure and Applied Chemistry (IUPAC) as (RS)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one, bupropion is a structurally unique monocyclic aminoketone. As an atypical antidepressant, it fundamentally diverges from the chemical architectures of classic tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and selective serotonin reuptake inhibitors (SSRIs), bearing a much closer resemblance to phenylethylamines and the anorectic agent diethylpropion.

Physicochemical Properties and Stereochemistry

The base molecular formula of the freebase is C_{13}H_{18}ClNO, corresponding to a molecular weight of 239.74 g/mol. In clinical formulations, it is predominantly synthesized and administered as a hydrochloride salt (C_{13}H_{18}ClNO \cdot HCl), which elevates its molecular weight to 276.20 g/mol. The freebase exists as a pale yellow oil, whereas the hydrochloride salt presents as a white, bitter-tasting crystalline powder that induces a sensation of local anesthesia upon contact with the oral mucosa.

Bupropion is a highly lipophilic and moderately basic compound. It possesses a partition coefficient (LogP) ranging between 3.2 and 3.6, which facilitates rapid and extensive penetration across the lipid bilayers of the blood-brain barrier (BBB). Its acid dissociation constant (pK_a) is approximately 7.9 to 8.35, dictating that the molecule exists predominantly in an ionized state at physiological pH levels (pH 7.4).

Structurally, bupropion contains a single chiral center at the C2 position of the aliphatic chain. Consequently, it is manufactured and administered clinically as a 50:50 racemic mixture of two enantiomers: R-(–)-bupropion and S-(+)-bupropion. While many modern pharmaceuticals rely on enantiopure isolations to maximize efficacy and reduce off-target toxicity, isolating a single enantiomer of bupropion for therapeutic use is practically futile. The R- and S-enantiomers undergo rapid stereochemical interconversion in aqueous physiological solutions, meaning the administration of an enantiopure formulation would rapidly revert to a racemate in vivo.

Parameter	Value / Description	Source
IUPAC Name	(RS)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
Empirical Formula	C_{13}H_{18}ClNO (Freebase) / C_{13}H_{18}ClNO \cdot HCl (Salt)
Molecular Weight	239.74 g/mol (Freebase) / 276.20 g/mol (HCl Salt)
LogP (Lipophilicity)	~3.2 - 3.6
pKa (Acid-Base)	~7.9 - 8.35
Melting Point	233-234 °C
Stereochemistry	Administered as a 50:50 racemate (rapid interconversion)

Structure-Activity Relationship (SAR) Profile

Bupropion is fundamentally a substituted cathinone, representing a \beta-keto analogue of amphetamine. Cathinone derivatives typically exert profound psychostimulant effects by acting as transportable substrates at monoamine transporters, reversing the normal direction of transporter flux to induce massive vesicular release of dopamine and norepinephrine. However, bupropion's pharmacological profile deviates entirely from classic, highly abusable synthetic cathinones (such as methcathinone) due to two critical, surgically precise structural modifications:

1. The Bulky tert-butyl Group: The addition of a massive, sterically hindering tert-butyl group to the amino nitrogen is the primary determinant of bupropion's unique safety profile and specific receptor mechanics. Deconstructed analogue studies reveal a distinct structure-activity threshold: \alpha-aminophenones with smaller amine substituents (like methyl, ethyl, or primary amines) are easily accommodated within the binding pockets of the dopamine (DAT) and norepinephrine (NET) transporters. Because they fit into the translocation machinery, these smaller analogues act as releasing agents.

Conversely, the immense steric bulk of the tert-butyl group in bupropion fundamentally alters its interaction with the transporter pore. The molecule is physically too large to be translocated across the presynaptic membrane. As a result, bupropion functions strictly as a non-transported reuptake inhibitor—wedging into the transporter and blocking the pore—rather than acting as a substrate. This mechanistic shift effectively eliminates the severe abuse liability and acute euphoric "rush" associated with amphetamine-like stimulants. Furthermore, this specific N-alkylation provides essential metabolic protection. The steric hindrance shields the nitrogen atom from rapid metabolic N-dealkylation by oxidative enzymes, granting the molecule a prolonged half-life and sustained therapeutic action compared to highly transient primary or secondary amines.

2. The meta-Chloro Substitution: The presence of a chlorine atom at the 3-position (meta) on the phenyl ring acts as the secondary pillar of bupropion's SAR. This halogen substitution alters the electron density and lipophilicity of the aromatic ring, directing the molecule's affinity profile. The meta-chloro configuration specifically steers the molecule's binding affinity away from the serotonin transporter (SERT) and almost exclusively toward DAT, NET, and nicotinic acetylcholine receptors (nAChRs). Removal of this chlorine atom (des-chlorobupropion) drastically degrades the molecule's targeted clinical efficacy, highlighting its role as an electronic modulator that defines the drug's purely catecholaminergic identity.

Level 2: Pharmacodynamics & Target Binding Profile

The therapeutic emergence of bupropion relies on a dual-action neurochemical mechanism: it functions simultaneously as a norepinephrine-dopamine reuptake inhibitor (NDRI) and as a potent, broad-spectrum non-competitive antagonist at specific nicotinic acetylcholine receptors (nAChRs).

Transporter Affinity (DAT, NET, and SERT)

At the monoaminergic synapses, bupropion acts as a relatively weak but highly selective competitive inhibitor of the physiological reuptake pumps for dopamine and norepinephrine.

Dopamine Transporter (DAT): In functional assays, bupropion inhibits the reuptake of dopamine with an IC_{50} typically ranging from 1.2 to 2.8 \mu M. Radioligand displacement studies utilizing human DAT reveal a binding affinity (K_i) of roughly 371 to 520 nM, making it a functional inhibitor, albeit with significantly lower potency than classical stimulants like cocaine or methylphenidate. Paradoxically, despite its clinical efficacy, human in vivo Positron Emission Tomography (PET) imaging indicates that clinical doses of bupropion (300 mg/day) result in surprisingly low striatal DAT occupancy—averaging only 14% to 26%. This suggests that simple DAT blockade alone cannot entirely explain its profound clinical utility.
Norepinephrine Transporter (NET): The substance demonstrates comparable, if not slightly superior, potency at NET, with an IC_{50} reported around 1.4 to 1.9 \mu M. The inhibition of NET leads to widespread noradrenergic pooling in cortical synapses.
Serotonin Transporter (SERT): Validating its SAR design, bupropion is clinically devoid of serotonergic activity. It shows a remarkably weak binding affinity (K_i) of approximately 45 \mu M at SERT, which completely insulates the drug from inducing the serotonergic side-effect profile (e.g., sexual dysfunction, emotional blunting, profound weight alterations) universally seen with SSRIs.

Nicotinic Acetylcholine Receptor (nAChR) Antagonism

Beyond its role as a reuptake inhibitor, bupropion acts as a non-competitive antagonist (NCA) of multiple nAChR subtypes. This mechanism is foundational to its widespread utility as a smoking cessation aid (marketed under the trade name Zyban).

Information gap exists regarding the exact nanomolar Ki binding affinities for specific human nAChR subtypes (e.g., alpha-4-beta-2, alpha-3-beta-4). Empirical consensus is lacking; the current literature primarily relies on micromolar IC_{50} functional values or binding data extrapolated from non-human homologous structures (such as the Torpedo californica electroplax) rather than precise human nanomolar K_i constants.

Based on available electrophysiological and radioligand assays, bupropion inhibits macroscopic cholinergic currents in a highly state-dependent manner. In Torpedo nAChR models, the photoreactive bupropion analogue SADU-3-72 demonstrates binding with high affinity (IC_{50} = 0.8 \mu M) in both the resting (closed channel) and agonist-induced desensitized states. Bupropion itself exhibits a distinct preference for the receptor's desensitized state (IC_{50} = 1.2 \mu M), binding with a three-fold higher affinity than to the resting closed-channel state (IC_{50} = 3.6 \mu M).

This non-competitive antagonism is driven by bupropion binding to two distinct loci within the receptor's transmembrane domain:

The Ion Channel Pore (M2-9): Bupropion exhibits a high-affinity binding site located deeply within the channel lumen at the M2-9 leucine ring (specifically interfacing with the \deltaLeu265 and \betaLeu257 residues). By physically lodging within this lumen, bupropion obstructs cation flux, demonstrating a voltage-independent channel blockade that cannot be surmounted by adding more acetylcholine or nicotine.
The \alphaM1 Extracellular Pocket: A secondary binding site is located near the extracellular end of the \alphaM1 helix (in proximity to \alphaTyr213). This region resides within a water-accessible binding pocket previously identified for general anesthetics (e.g., halothane). Binding at this specific site is enhanced more than tenfold when the receptor enters an agonist-induced desensitized state.

In functional assays utilizing human cell lines, bupropion effectively inhibits human \alpha_4\beta_2 receptors (the primary subtype mediating the reinforcing effects of nicotine addiction) and \alpha_3\beta_4 receptors (involved in ganglionic transmission and withdrawal aversion) with IC_{50} values of approximately 12 \mu M and 1.8 to 15 \mu M, respectively. The general rank order of inhibitory potency across the nAChR spectrum is \alpha_3- > \alpha_1- \approx \alpha_4- > \alpha_7-containing receptors.

Additionally, bupropion has been identified as a negative allosteric modulator at the 5-HT3A receptor—a structurally related member of the Cys-loop ligand-gated ion channel superfamily—with an IC_{50} of 87 \mu M. While weak, this auxiliary blockade may subtly contribute to its broader neuropsychiatric and anti-emetic profile.

Level 3: Pharmacokinetics (ADME Profile)

Bupropion exhibits an exceptionally complex, stereoselective pharmacokinetic profile that is heavily dictated by extensive presystemic hepatic clearance and highly variable chiral metabolism.

Absorption and Formulation Kinetics

Upon oral administration, bupropion is rapidly and almost completely absorbed from the gastrointestinal tract. However, the drug is subjected to an extremely aggressive first-pass hepatic extraction. Consequently, the absolute systemic bioavailability of the unchanged parent drug is estimated to be quite low, ranging from a mere 5% to 20% in human subjects.

Because the parent compound is a potent pro-convulsant at high peak plasma concentrations (C_{max}), the pharmaceutical release kinetics strictly dictate safety and tolerability. The drug is engineered into three primary formulations to control the absorption rate and mitigate steep peak-to-trough fluctuations:

Formulation Type	Dosing Frequency	Time to Peak Plasma Concentration (T_{max})	Elimination Half-Life (t_{1/2}) of Parent
Immediate Release (IR)	Thrice Daily (TID)	~1.5 to 2 hours	~10 to 14 hours
Sustained Release (SR)	Twice Daily (BID)	~3 hours	~14 hours
Extended Release (XL)	Once Daily (QD)	~5 hours	~21 hours

Data aggregated from. Note: While T_{max} varies drastically to flatten the absorption curve, the overall Area Under the Curve (AUC) remains bioequivalent across formulations.

Distribution

Reflecting its high lipophilicity (LogP ~3.6), bupropion is widely distributed throughout bodily tissues. The apparent volume of distribution (V_d) is massive, estimated between 19 L/kg and 47 L/kg. This extensive tissue penetrance ensures that both the parent drug and its active metabolites rapidly cross the Blood-Brain Barrier (BBB) to engage central monoaminergic and cholinergic targets. Plasma protein binding is moderately high but varies among the molecular species: the parent compound binds at approximately 84%, hydroxybupropion at 77%, and threohydrobupropion at roughly 42%.

Metabolism

Bupropion undergoes extensive hepatic biotransformation, yielding three primary, pharmacologically active metabolites that circulate in the plasma at concentrations vastly exceeding the parent drug.

Hydroxybupropion: Formed via the direct oxidation (hydroxylation) of the tert-butyl group, this reaction is almost exclusively catalyzed by the hepatic cytochrome P450 enzyme CYP2B6. Because of its prolonged half-life, hydroxybupropion accumulates exponentially. At steady state, hydroxybupropion achieves an AUC and C_{max} approximately 10 to 17 times higher than that of bupropion itself. Hydroxybupropion retains roughly 50% of the pharmacological potency of the parent drug and is critically implicated in driving both the therapeutic efficacy (especially for smoking cessation) and the toxicological side effects of the regimen. Genetic polymorphisms in CYP2B6 (such as the *1/*6 or *6/*6 variant alleles) drastically reduce hydroxybupropion formation, leading to highly variable clinical responses and altered toxicity thresholds among different patients.
Threohydrobupropion & Erythrohydrobupropion: These two active metabolites are formed not by CYP enzymes, but via the stereoselective reduction of the central ketone group by ubiquitous carbonyl reductases (specifically HSD11B1 in the liver and AKR7 in the intestine). Threohydrobupropion achieves an AUC approximately 5 times greater than the parent drug, while erythrohydrobupropion circulates at levels roughly equal to the parent. Both retain approximately 20% of bupropion's baseline noradrenergic and dopaminergic activity.

Metabolism is also profoundly stereoselective. For example, S-bupropion is metabolized much more rapidly into corresponding active stereoisomers (e.g., S,S-hydroxybupropion) compared to its R-enantiomer counterpart, leading to highly asymmetric plasma concentrations of specific chiral metabolites over time.

Information gap exists regarding the precise fractional contribution of its active metabolite (hydroxybupropion) versus the parent compound to the overall in vivo clinical effect. Because hydroxybupropion circulates at levels up to 17 times higher than the parent, but possesses only 50% of the in vitro potency at DAT/NET, calculating the exact fractional in vivo contribution of each molecule to the holistic antidepressant response remains an unresolved debate in clinical pharmacology.

Excretion

The terminal elimination half-life (t_{1/2}) of the parent bupropion molecule spans roughly 12 to 21 hours depending on the formulation. However, the active metabolites exhibit significantly prolonged elimination kinetics: hydroxybupropion clears in \sim 20 hours, erythrohydrobupropion in \sim 33 hours, and threohydrobupropion lingers for \sim 37 hours. Elimination is almost entirely renal; approximately 87% of an administered dose is excreted in the urine (exclusively as highly polar glucuronidated metabolites, with less than 1% excreted as the unchanged parent drug), while roughly 10% is eliminated via the feces.

Level 4: Downstream Cellular Signaling & Local Tissue Shifts

At the level of local neural circuits, bupropion initiates a complex, divergent cascade of intracellular signaling driven by its simultaneous actions on monoamine transporters and cholinergic ion channels.

The Monoaminergic Excitatory Cascade: In the catecholaminergic system, bupropion's competitive blockade of presynaptic DAT and NET abruptly halts the physiological reuptake of dopamine and norepinephrine. This failure of clearance leads to localized extracellular pooling of these monoamines within the synaptic cleft. The sustained high concentrations of neurotransmitters cause prolonged activation of post-synaptic G-protein coupled receptors (GPCRs). This sustained GPCR engagement robustly activates the intracellular enzyme adenylyl cyclase (AC), which in turn catalyzes the conversion of ATP into cyclic AMP (cAMP). The ensuing surge in intracellular cAMP activates Protein Kinase A (PKA), triggering a downstream phosphorylation cascade that ultimately alters gene transcription (e.g., via CREB) and upregulates brain-derived neurotrophic factor (BDNF). This long-term shift in neuroplasticity and synaptic growth is fundamentally responsible for alleviating depressive anhedonia.

The Cholinergic Inhibitory Cascade: Simultaneously, within the reward circuitry, bupropion blunts neuronal depolarization via its non-competitive nAChR antagonism. By physically wedging into the cation pore of \alpha_4\beta_2 receptors located on dopaminergic and GABAergic neurons in the ventral tegmental area (VTA), bupropion prevents the rapid influx of calcium (Ca^{2+}) and sodium (Na^+) normally triggered by acetylcholine or exogenous nicotine. This failure to depolarize effectively silences the downstream burst-firing release of dopamine into the nucleus accumbens. By dampening this cholinergic-mediated dopamine spike, bupropion neurologically decouples the physical act of smoking from the physiological sensation of reward, neutralizing the chemical reinforcement of addiction.

Level 5: Up/Down-Regulation Mechanics & Tolerance Kinetics

While the pharmacokinetic blockade of DAT/NET and nAChRs occurs within hours of oral ingestion, the clinical efficacy of bupropion—particularly its profound antidepressant effect—requires a chronologic timeline of weeks to emerge. This delay is mediated by the slow kinetics of receptor adaptation and genomic regulation in response to sustained drug exposure.

Chronic exposure to bupropion, and the resulting sustained elevation of synaptic norepinephrine and dopamine, triggers robust homeostatic mechanisms. Biochemical models indicate that chronic administration leads to the pronounced down-regulation of post-synaptic \beta-adrenoceptors in the cortex. Furthermore, the adenylyl cyclase enzyme system itself undergoes desensitization, becoming less responsive to norepinephrine stimulation over time.

Conversely, in the dopaminergic system, in vivo microdialysis studies demonstrate that chronic administration actually enhances bupropion-induced increases in extracellular dopamine in the nucleus accumbens. This is likely due to the gradual down-regulation and desensitization of inhibitory presynaptic D_2 autoreceptors. Initially, these autoreceptors curb dopamine release upon acute exposure, but as they desensitize, the "brakes" are removed, allowing for more robust dopaminergic signaling as treatment progresses.

Crucially, this systemic neuroadaptation is accompanied by a specific, dose-dependent lowering of the global seizure threshold. The pro-convulsant mechanism is deemed multifactorial, driven by the chronic accumulation of the parent drug and its active metabolites. The threshold shift is thought to result from altered firing rates in the locus coeruleus and shifting balances between excitatory (glutamatergic/monoaminergic) and inhibitory (GABAergic) networks across the cortex, making the brain increasingly susceptible to unheralded epileptiform discharges as dosage escalates.

Level 6: Systemic, Peripheral & Neuroanatomical Topography

Central Topography

Bupropion targets highly specific functional topographies within the central nervous system to exert its clinical effects.

The Mesolimbic Reward Pathway: Bupropion exerts profound modulatory effects on the neural projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc). By antagonizing \alpha_4\beta_2 nAChRs specifically on VTA neurons, it directly blunts the reward-prediction errors and dopamine surges associated with nicotine consumption, neutralizing cravings.
The Prefrontal Cortex (PFC): Resting-state functional magnetic resonance imaging (fMRI) studies demonstrate that bupropion significantly alters functional topography in the cortex. Relative to placebo, bupropion increases resting-state functional connectivity (RSFC) between the dorso-medial prefrontal cortex (dmPFC) seed region and the posterior cingulate cortex as well as the precuneus. This activation of the default mode network and executive control circuits correlates strongly with improvements in focus, motivation, and the reversal of depressive anhedonia.
The Habenulo-Interpeduncular Pathway: Antagonism of \alpha_3\beta_4 nAChRs in this specific aversion-related circuit contributes to the blunting of the negative affective state and somatic distress experienced during nicotine withdrawal.

Peripheral and Systemic Physiology

Peripherally, bupropion acts as a mild sympathomimetic due to the sustained elevation of circulating norepinephrine. Patients routinely present with predictable autonomic shifts: mild resting tachycardia, marginal elevations in blood pressure (which can exacerbate pre-existing hypertension), diaphoresis (excessive sweating), and xerostomia (dry mouth).

However, bupropion is defined as much by the side effects it lacks as the ones it produces. Because its meta-chloro SAR profile leaves it utterly devoid of significant serotonergic, histaminergic, or anticholinergic affinity, it does not induce the typical side effects that plague SSRIs and TCAs. It does not induce emotional blunting or somnolence. Most notably, it does not cause serotonin-mediated sexual dysfunction; in fact, its dopaminergic tone often reverses SSRI-induced libido loss. Furthermore, it is entirely weight-neutral and frequently induces modest, dose-dependent weight loss, contrasting sharply with the severe metabolic disruption and lipid accumulation associated with most psychiatric medications.

Level 7: Network-Level Effects & Drug-Drug Interactions (DDI)

Scaling from local tissue shifts to global network effects, bupropion acts as a formidable pharmacological perpetrator, drastically altering systemic metabolic networks and necessitating extreme caution in polypharmacy.

The CYP2D6 Inhibition Paradigm

Although bupropion is primarily cleared by CYP2B6, both the parent drug and its massive pool of circulating metabolites are potent, competitive inhibitors of the CYP2D6 enzyme system. Physiologically-based pharmacokinetic (PBPK) modeling reveals a critical insight: while bupropion alone is a relatively weak in vitro inhibitor (IC_{50} = 21 \mu M), its chiral metabolites—particularly S,S-hydroxybupropion and erythrohydrobupropion—accumulate to such extreme steady-state plasma concentrations that they act as severe in vivo inhibitors. Furthermore, evidence suggests that these metabolites not only competitively bind to the enzyme but also trigger transcriptional down-regulation of CYP2D6 mRNA, compounding the inhibitory effect.

This inhibition completely derails the pharmacokinetic profile of co-administered CYP2D6 substrates:

Dextromethorphan (Intentional Synergy): Bupropion drastically blocks the rapid O-demethylation of dextromethorphan into its less active metabolite, dextrorphan. This interaction has been intentionally engineered into the FDA-approved combination drug Auvelity. Bupropion's inhibition extends the half-life and dramatically spikes the plasma concentration of dextromethorphan, allowing it to exert sustained uncompetitive NMDA-receptor antagonism to yield rapid-acting antidepressant effects.
Antidepressants & Antipsychotics (Toxicity Risk): Bupropion can induce up to a five-fold exponential increase in the systemic exposure of tricyclic antidepressants (e.g., desipramine) and SSRIs/SNRIs (e.g., venlafaxine, paroxetine, fluoxetine), requiring aggressive, pre-emptive dose reductions to prevent fatal serotonin syndrome or cardiovascular toxicity.
Opioid Analgesic Failure: As a strong CYP2D6 inhibitor, bupropion completely halts the essential bioactivation of prodrug opioids. Medications such as codeine and tramadol rely on CYP2D6 to be converted into their active, highly potent analgesic metabolites (e.g., morphine and O-desmethyltramadol). Co-administration with bupropion renders these painkillers therapeutically useless while maintaining their baseline side effects.

Absolute Contraindications

Due to bupropion's unique capacity to lower the global seizure threshold, it exhibits fatal synergism when combined with other pro-convulsant medications (e.g., tramadol, theophylline, systemic corticosteroids). It is strictly and absolutely contraindicated in patients undergoing abrupt withdrawal from alcohol, benzodiazepines, or sedatives, as well as in patients with anorexia nervosa or bulimia, whose inherent electrolyte imbalances render the bupropion-induced seizure risk catastrophically high. Finally, co-administration with Monoamine Oxidase Inhibitors (MAOIs) requires a mandatory 14-day absolute washout period; overlapping these pathways results in a fatal hypertensive crisis due to unconstrained catecholamine accumulation.

Level 8: Real-World Emergence (Subjective/Objective Actions & Toxicology)

Clinical Utility

In formalized clinical practice, bupropion is FDA-approved for Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an adjunctive smoking cessation aid (under the brand name Zyban). Off-label, its precise dopaminergic and noradrenergic modulation is heavily leveraged by psychiatrists to treat Attention-Deficit/Hyperactivity Disorder (ADHD), to rapidly counter SSRI-induced sexual dysfunction, and to combat the crushing lethargy often associated with bipolar depression.

Toxicology and Overdose Pathology

When therapeutic limits are exceeded, either accidentally or intentionally, bupropion overdose presents with a severe, highly specific, and life-threatening toxidrome. Retrospective epidemiological analyses indicate that seizures are the hallmark of toxicity, occurring in 17% to 47% of significant overdose cases, frequently advancing to refractory status epilepticus. Accompanying neurological and autonomic symptoms include profound agitation, visual hallucinations, severe hyperreflexia, extreme resting tachycardia, and lactic acidosis resulting from sustained muscular tremors. Extended-release (XL/SR) ingestions represent a highly pernicious toxicological threat; due to the slow-release matrix, the onset of violent seizures can be entirely unheralded and delayed up to 24 hours post-ingestion, requiring prolonged intensive care observation even for asymptomatic patients.

Cardiotoxic Mechanisms (Gap Junction Failure): Massive overdose triggers lethal cardiovascular collapse characterized by profound QRS complex widening and QT prolongation. Critically, unlike classic tricyclic antidepressants wherein QRS widening is driven by the blockade of cardiac fast sodium channels, bupropion-induced QRS prolongation is completely independent of sodium channel blockade. Instead, massive bupropion exposure directly inhibits myocardial gap junctions (specifically targeting Connexin-43 proteins and inward-rectifier potassium channels). This severely disrupts intercellular electrical coupling across the myocardium, leading to progressive electromechanical dissociation and pulseless electrical activity (PEA).

Because the underlying pathological mechanism is gap junction failure rather than fast sodium channel blockade, traditional resuscitative protocols utilizing massive sodium bicarbonate boluses are largely ineffective at narrowing the QRS interval. In cases of refractory cardiogenic shock induced by bupropion, heroic and unconventional interventions such as high-dose intravenous lipid emulsion (ILE) therapy or veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are required to maintain perfusion until the highly lipophilic drug can be cleared.

Level 8.5: Phenomenological Consensus, Anecdotal Topography & Real-World Use

Crucial Distinction Protocol: Community consensus indicates the following phenomenological data, compiled from crowdsourced harm-reduction databases (e.g., Erowid, PsychonautWiki, Reddit). This section aggregates qualitative self-reports regarding the subjective human experience of bupropion at supra-therapeutic or recreational dosages. All data in this tier must be explicitly separated from the peer-reviewed clinical pharmacology established in Levels 1-8.

Subjective Effect Profiling

Cognitive Effects: Community consensus indicates that bupropion generates a clear, but distinctly "hollow" or "functional" stimulation. Users frequently report increased motivation, prolonged wakefulness, and hyper-focus conducive to completing mundane tasks. However, unlike classic amphetamines, cocaine, or its illicit chemical cousin methcathinone, bupropion is universally reported to lack any euphoric "rush" or empathogenic warmth. Because the drug acts purely as a reuptake inhibitor with relatively slow DAT binding kinetics—and because the bulky tert-butyl group precludes the vesicular release of dopamine—supratherapeutic doses fail to trigger the profound dopaminergic reward signaling sought by recreational users. Instead, dose escalation consistently yields aggressive, uncomfortable stimulation, severe physical anxiety, and dysphoric agitation, often bordering on stimulant-induced psychosis, paranoia, or severe panic attacks during the peak plasma phase.

Sensory & Perceptual Effects: A prominent and highly reported sensory disturbance among the community is the onset of drug-induced tinnitus (a persistent ringing, humming, or buzzing in the ears). Community consensus closely mirrors emerging clinical case reports, confirming that tinnitus perception is intimately tied to dose escalation (e.g., moving from 150 mg to 300 mg/day). The exact pathophysiology remains heavily debated but is presumed by users to be linked to altered noradrenergic and dopaminergic signaling within the auditory temporal-parietal networks. It is generally reversible upon dose reduction or total discontinuation of the medication.

Somatic & Physical Effects: Physically, bupropion exacts a heavy sympathomimetic toll at recreational doses. Users report profound, inescapable insomnia, bruxism (severe jaw clenching), diaphoresis, resting tachycardia, and intense, fine muscle tremors in the extremities.

The Insufflation Hazard: Community consensus explicitly and fiercely warns against the practice of crushing and insufflating (snorting) bupropion pills—a highly dangerous practice sometimes erroneously attempted by naïve users as a "poor man's cocaine". Phenomenological reports indicate that insufflation results in excruciating pain, epistaxis (nosebleeds), and caustic chemical burns to the nasal mucosal tissue. More dangerously, crushing the pills immediately destroys the structural polymer matrix of Sustained-Release (SR) and Extended-Release (XL) formulations. This dumps a massive, immediate payload of bupropion directly into the highly vascularized nasal membrane, violently spiking plasma concentrations and bypassing first-pass liver metabolism. This practice frequently results in sudden, unheralded generalized tonic-clonic seizures within minutes of ingestion.

Community Dosage & Timeline Consensus

Harm-reduction communities are fiercely unified on the absolute dosage ceiling: exceeding 450 mg per day is categorically dangerous. The community-agreed limits acknowledge that pushing past the 450 mg threshold dramatically spikes the seizure risk exponentially, without providing any concomitant increase in positive cognitive or mood-lifting effects. Bupropion is widely considered to possess zero recreational value at high doses, operating strictly as a functional, low-level stimulant that rapidly becomes neurotoxic when pushed.

Set, Setting & Synergy

In practical application, community reports heavily highlight the strategic synergy of bupropion when combined with serotonergic antidepressants (SSRIs). It is highly prized as a combination agent (often colloquially referred to as "Welloft" when combined with Zoloft) to combat the specific lethargy, emotional blunting, and sexual dysfunction induced by the SSRI. By layering bupropion's dopaminergic and noradrenergic stimulation over an SSRI's serotonergic foundation, users report a restoration of libido, physical energy, and executive function, creating a balanced, multi-monoamine clinical effect that mitigates the side effects of either drug taken in isolation.

Works cited

1. Bupropion =98 HPLC,solid 31677-93-7 - Sigma-Aldrich, https://www.sigmaaldrich.com/US/en/product/sigma/b102

2. Wellbutrin (bupropion hydrochloride) tablets label - accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf

3. Bupropion - Wikipedia, https://en.wikipedia.org/wiki/Bupropion

4. Bupropion | C13H18ClNO | CID 444 - PubChem - NIH, https://pubchem.ncbi.nlm.nih.gov/compound/Bupropion

5. Bupropion D9 | C13H18ClNO | CID 25235328 - PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bupropion-D9

6. Bupropion Hydrochloride | C13H19Cl2NO | CID 62884 - PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bupropion-Hydrochloride

7. Compound: BUPROPION (CHEMBL894) - ChEMBL - EMBL-EBI, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL894

8. Bupropion: Definition, Properties, Mechanism of Action and Uses - BOC Sciences, https://www.bocsci.com/resources/bupropion-definition-properties-mechanism-of-action-and-uses.html

9. Neuropharmacology of Synthetic Cathinones - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7257813/

10. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7261150/

11. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release | ACS Chemical Neuroscience, https://pubs.acs.org/doi/10.1021/acschemneuro.7b00055

12. tert-Butyl Ethers - Organic Chemistry Portal, https://www.organic-chemistry.org/protectivegroups/hydroxyl/tert-butyl-ethers.htm

13. Metabolic N-Dealkylation and N-Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors - Semantic Scholar, https://pdfs.semanticscholar.org/4f2e/3deb547d7c96acd94809260788c899748359.pdf

14. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release - ResearchGate, https://www.researchgate.net/publication/313888950_Deconstructed_Analogues_of_Bupropion_Reveal_Structural_Requirements_for_Transporter_Inhibition_versus_Substrate-Induced_Neurotransmitter_Release

15. Bupropion binds to two sites in the Torpedo nicotinic acetylcholine receptor transmembrane domain: a photoaffinity labeling study with the bupropion analogue [(125)I]-SADU-3-72 - PubMed, https://pubmed.ncbi.nlm.nih.gov/22394379/

16. Bupropion is a nicotinic antagonist - PubMed - NIH, https://pubmed.ncbi.nlm.nih.gov/10991997/

17. Bupropion is a nicotinic antagonist. - ClinPGx, https://www.clinpgx.org/pmid/10991997

18. bupropion [Ligand Id: 7135] activity data from GtoPdb and ChEMBL - IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/LigandActivityRangeVisForward?ligandId=7135

19. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. - ClinPGx, https://www.clinpgx.org/pmid/15322260

20. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. - ClinPGx, https://www.clinpgx.org/literature/11695532

21. Bupropion occupancy of the dopamine transporter is low during clinical treatment | Request PDF - ResearchGate, https://www.researchgate.net/publication/11202874_Bupropion_occupancy_of_the_dopamine_transporter_is_low_during_clinical_treatment

22. Bupropion occupancy of the dopamine transporter is low during clinical treatment - PubMed, https://pubmed.ncbi.nlm.nih.gov/12185406/

23. Bupropion XL and SR Have Similar Effectiveness and Adverse Event Profiles When Used to Treat Smoking Among Patients at a Comprehensive Cancer Center - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9117427/

24. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant, https://pmc.ncbi.nlm.nih.gov/articles/PMC4837968/

25. Bupropion Binds to Two Sites in the Torpedo Nicotinic Acetylcholine Receptor Transmembrane Domain - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3315157/

26. Molecular interaction of bupropion with nicotinic acetylcholine receptors, https://scholars.okstate.edu/en/publications/molecular-interaction-of-bupropion-with-nicotinic-acetylcholine-r/

27. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors | Request PDF - ResearchGate, https://www.researchgate.net/publication/308697466_The_antidepressant_bupropion_is_a_negative_allosteric_modulator_of_serotonin_type_3A_receptors

28. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations, https://pubmed.ncbi.nlm.nih.gov/16368442/

29. Bupropion - StatPearls - NCBI Bookshelf - NIH, https://www.ncbi.nlm.nih.gov/books/NBK470212/

30. Clinical pharmacokinetics of bupropion: a review - PubMed, https://pubmed.ncbi.nlm.nih.gov/6406470/

31. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects, http://www.ricardinis.pt/wp-content/uploads/2019/06/Pharmacokinetic-and-pharmacodynamic-of-bupropion-integrative-overview-of-relevant-clinical-and-forensic-aspects.pdf

32. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10317506/

33. Bupropion Formulations & Dosing: IR vs. SR vs. XL – Which to Choose?, https://shanghaiarchivesofpsychiatry.org/bupropion-formulations-dosing/

34. What are the half-lives of Bupropion (Immediate Release) IR, (Sustained Release) SR, and (Extended Release) XL? - Dr.Oracle, https://www.droracle.ai/articles/280728/what-are-the-half-lives-of-bupropion-immediate-release-ir

35. 15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC1163271/

36. Bupropion Toxicity - StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK580478/

37. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers - ResearchGate, https://www.researchgate.net/publication/318252023_Pharmacokinetics_and_Pharmacogenomics_of_Bupropion_in_Three_Different_Formulations_with_Different_Release_Kinetics_in_Healthy_Human_Volunteers

38. Bupropion Pathway, Pharmacokinetics - ClinPGx, https://www.clinpgx.org/pathway/PA166170276

39. Summary annotation for CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22, CYP2B6*30; bupropion (level 2A Metabolism/PK) - ClinPGx, https://www.clinpgx.org/summaryAnnotation/1445421156

40. Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9832377/

41. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4959100/

42. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5164944/

43. Hydroxybupropion - Wikipedia, https://en.wikipedia.org/wiki/Hydroxybupropion

44. Bupropion - Mechanism of Action | Psychopharmacology | Clinical Application - Psych Scene Hub, https://psychscenehub.com/wp-content/uploads/2021/03/40_Bupropion-%E2%80%93-Mechanism-of-Action-_-Psychopharmacology.pdf

45. Adenylyl cyclase-cyclicAMP signaling in mood disorders: Role of the crucial phosphorylating enzyme protein kinase A - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC2515915/

46. Adenylyl Cyclases as Therapeutic Targets in Neuroregeneration - MDPI, https://www.mdpi.com/1422-0067/26/13/6081

47. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area - PubMed, https://pubmed.ncbi.nlm.nih.gov/17868653/

48. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC514842/

49. Bupropion: a review of its mechanism of antidepressant activity - PubMed, https://pubmed.ncbi.nlm.nih.gov/7665537/

50. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain - PubMed, https://pubmed.ncbi.nlm.nih.gov/6320035/

51. A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers - Frontiers, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00482/full

52. Bupropion Administration Increases Resting-State Functional Connectivity in Dorso-Medial Prefrontal Cortex - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5458340/

53. Neurobiological Mechanisms of Nicotine Reward and Aversion - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11060337/

54. Bupropion Administration Increases Resting-State Functional Connectivity in Dorso-Medial Prefrontal Cortex - PubMed, https://pubmed.ncbi.nlm.nih.gov/28340244/

55. Seizures After Overdoses of Bupropion Intake - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4115959/

56. Bupropion Overdose - Emergency Care BC, https://emergencycarebc.ca/clinical_resource/clinical-summary/bupropion-overdose/

57. Bupropion-induced tinnitus after dose escalation: a rare and reversible adverse effect - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12688901/

58. Annotation of FDA Label for bupropion and CYP2D6 - ClinPGx, https://www.clinpgx.org/labelAnnotation/PA166223861

59. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5874814/

60. (PDF) Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network - ResearchGate, https://www.researchgate.net/publication/349912707_Physiologically_Based_Pharmacokinetic_Modeling_of_Bupropion_and_Its_Metabolites_in_a_CYP2B6_Drug-Drug-Gene_Interaction_Network

61. Inhibition of CYP2D6 activity by bupropion - PubMed - NIH, https://pubmed.ncbi.nlm.nih.gov/15876900/

62. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers | FDA, https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers

63. Dextromethorphan & Bupropion: Pharmacology, Indications, Dosing Guidelines and Adverse Effects | Psychopharmacology Institute, https://psychopharmacologyinstitute.com/publication/dextromethorphan-bupropion-pharmacology-indications-dosing-guidelines-and-adverse-effects-2937/

64. Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6 - ClinPGx, https://www.clinpgx.org/labelAnnotation/PA166278361

65. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model - MDPI, https://www.mdpi.com/1999-4923/10/1/1

66. Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm - MDPI, https://www.mdpi.com/1999-4923/17/2/179

67. Tramadol Therapy and CYP2D6 Genotype - Medical Genetics Summaries - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK315950/

68. UTAH MEDICAID DUR REPORT FEBRUARY 2022 CODEINE USE IN CHILDREN, https://www.utah.gov/pmn/files/810713.pdf

69. WELLBUTRIN - accessdata.fda.gov, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018644s039s040.pdf

70. Auvelity - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215430s000lblCorrect3.pdf

71. Dextromethorphan - StatPearls - NCBI Bookshelf - NIH, https://www.ncbi.nlm.nih.gov/books/NBK538216/

72. Bupropion Overdose and Management | Poison Control | University of Utah Health, https://poisoncontrol.utah.edu/news/2021/05/bupropion-overdose-and-management

73. Electrocardiographic Effects of Bupropion Toxicity Suggesting Dysfunction of the Gap Junction or Connexin 43 - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11018313/

74. QRS widening from Bupropion and NaHCO3 administration - UMEM Educational Pearls - University of Maryland School of Medicine, Department of Emergency Medicine, https://umem.org/educational_pearls/4432/

75. Bupropion Toxicity - EMRA, https://www.emra.org/emresident/article/bupropion-toxicity

76. Bupropion mechanism of cardiotoxicity: • Na+ blockade slows conduction → progressive electrical failure instead of reentrant, https://scholarlycommons.hcahealthcare.com/cgi/viewcontent.cgi?article=1033&context=westflorida2025

77. Partially Reversible Tinnitus Associated with Bupropion: A Case Highlighting the Importance of Dosage Adjustment | Psychiatric Times, https://www.psychiatrictimes.com/view/partially-reversible-tinnitus-associated-with-bupropion-a-case-highlighting-the-importance-of-dosage-adjustment

78. Bupropion-induced tinnitus after dose escalation: a rare and reversible adverse effect - a case report - PubMed, https://pubmed.ncbi.nlm.nih.gov/41377339/

79. An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System - PubMed, https://pubmed.ncbi.nlm.nih.gov/25308323/

80. Bupropion abuse and overdose - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4162783/